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Abstract 
Obstructive sleep apnoea (OSA) has been reported to be associated with brain hypotrophy and 
cognitive dysfunction; however, whether these normalise after treatment is unclear. The overall aim 
of this thesis is to investigate the relationship between OSA and brain structure using FreeSurfer (a 
new automated technique that reliably measures brain structures). I have investigated changes in 
brain morphology and the newly described phenomenon in OSA of ischaemic preconditioning. 
Chapters 4 and 5 will also assess brain structural response to CPAP, and investigate the association 
between brain structure and cognitive function in OSA. 
Chapter 3 reports an observational study investigating brain structure. FreeSurfer analysis of magnetic 
resonance imaging (MRI) found OSA patients had hypertrophy in the right hippocampus (p=0.03) and 
right choroid plexus (p=0.02) but hypotrophy of the corpus callosum (p=0.04) compared to healthy 
controls. 
Chapter 4 reports a randomised controlled trial of CPAP in OSA. At baseline hypotrophy was seen in 
the corpus callosum (p=0.03) and pallidum (p=0.03) of OSA patients compared to healthy controls. 
Hypertrophic changes in the right thalamus were seen in the CPAP group after 1 month (p=0.06), 
associated with improvement in verbal memory (p=0.04).   
Chapter 5 reports a randomised controlled trial of CPAP in older patients with OSA. A significant 
decrease in left fimbria volume was seen in the CPAP group (p=0.01). A significant increase in the left 
presubiculum volume was seen in the best supportive care group (p=0.03). No hippocampal 
hypertrophy was seen in the CPAP group. 
In summary, young and middle-aged OSA patients had evidence of brain hypotrophy, but also areas 
of hypertrophy that may signify dendritic sprouting and increased connectivity as a result of ischaemic 
preconditioning. This allows recovery of brain hypotrophy after CPAP treatment. This was not seen in 
older OSA patients suggesting an age-related difference which may have implications for OSA 
treatment in older people.  
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1.1  OVERVIEW 
Obstructive sleep apnoea (OSA) is the name given to repetitive episodes of sleep-related upper airway 
collapse, which occlude the airway and lead to hypoxaemia plus hypercapnaemia. These periods of 
sleep apnoea are frequently terminated by arousal from sleep, which can lead to symptoms of 
sleepiness, as well as cardiovascular disease and neurocognitive impairment. The cognitive 
impairment associated with OSA is the particular focus of the studies presented in this thesis. 
Chapter 1 outlines the aetiology, pathophysiology and epidemiology of OSA, as well as a brief 
discussion of some of its sequelae. The neurological consequences of OSA will be reviewed focusing 
on cognitive impairment. The chapter will also describe the cognitive domains that are thought to be 
affected by OSA, as well as the functional outcomes e.g. driving impairment. Possible mechanisms of 
cognitive impairment will be considered. These will focus on a) attention deficits as a result of 
sleepiness, b) changes in brain structure as a result of either intermittent hypoxia or sleep 
fragmentation. The different methods of assessing cognitive function, brain structure and sleepiness 
will be included in Chapter 2. The final section of Chapter 1 will list the specific aims of the thesis. 
 
1.2   OBSTRUCTIVE SLEEP APNOEA 
OSA is at the severe end of a disease spectrum referred to as ‘sleep disordered breathing’ (Fig 1.1). 
Snoring and nocturnal airflow limitation (sometimes called ‘upper airway resistance syndrome’) is at 
the mild end, and complete obstruction resulting in cessation of airflow (apnoea) is at the other. Partial 
obstruction of the upper airway is in the middle of the disease severity spectrum, and results in 
reduction of airflow termed ‘hypopnoea’. The definition of what constitutes a hypopnea varies but it 
is often considered that a 50% reduction in airflow, in combination with a 4% decrease in arterial 
oxygen saturations or an arousal from sleep is classed as a hypopnoea (see Chapter 2 for more details). 
OSA severity is described by the apnoea-hypopnoea index (AHI). This is the mean number of apnoeas 
and hypopnoeas per hour of sleep. OSA is defined as 5 events or more per hour. Mild OSA is usually 
an AHI less than 15 events per hour. Moderate OSA is defined as an AHI between 15 and 30 events 
per hour, and an AHI greater than 30 events per hour is considered severe (Fig 1.1). Obstructive sleep 
apnoea-hypopnoea syndrome (OSAHS) is defined as the presence of OSA in combination with 
excessive daytime sleepiness. 
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Figure 1.1: The spectrum of disease referred to as ‘sleep disordered breathing’. UAR: Upper airway 
resistance, OSA: Obstructive sleep apnoea, AHI: Apnoea/Hypopnoea Index 
 
1.2.1 The aetiology of OSA 
The aetiology of OSA is complex and multi-factorial. In simple terms the cycle of OSA is produced by 
upper airway occlusion leading to apnoea, which in turn produces changes in blood gases, and a 
subsequent arousal from sleep that triggers the airway re-opening and the resumption of airflow (Fig 
1.2). This section will give an overview of the factors that contribute to the development of OSA. 
 
Figure 1.2 The cycle of obstructive sleep apnoea 
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Upper airway narrowing in OSA: The most common site of upper airway collapse in patients with OSA 
is the retroglossal airway; (fig 1.3). However, narrowing can occur at different points along the airway 
and any condition that leads to upper airway narrowing will predispose to OSA (Dempsey et al., 2010), 
including craniofacial abnormalities (Mixter et al., 1990; Pijpers et al., 2004), enlargement of upper 
airway soft tissue structures (Hwang et al., 2013) and external compression due to obesity (Pahkala et 
al., 2013) or oedema (Redolfi et al., 2009). However, it is important to note that people with 
anatomical narrowing of the upper airways are able to maintain airway patency during wakefulness, 
and it is only during sleep that airway obstruction occurs.  
 
Figure 1.3 Midsagital MRI in a normal subject (left) and a patient with Severe OSA (Apnoeic – Right). 
Highlighted are the 4 regions of the pharynx, the upper airway soft tissues and craniofacial structures 
that can contribute to OSA. Fat tissue is shown in white. Note that the OSA patient has more fat tissue 
around the neck, and in the tongue. He/She also has a smaller retroplatal and retroglossal airway 
(Dempsey et al., 2010). 
 
Hypoventilation during sleep: The respiratory minute volume in healthy individuals has been shown 
to be up to 15% lower during sleep, compared to wakefulness (Douglas et al., 1982). A number of 
factors contribute to this reduction. During wakefulness there is a ventilatory drive from the cortex 
called the ‘Wakefulness Drive to Breathe’. This cortical drive is absent during sleep (Fink, 1961; Morrell 
et al., 1993; Wellman et al., 2004). Furthermore, a simultaneous sleep-related reduction in 
chemosensitivity also occurs (Dempsey & Skatrud, 1986). These two factors reduce the ventilatory 
drive to the respiratory pump muscles, which produces a relative hypercapnia during sleep (Dempsey 
& Skatrud, 1986; Leevers et al., 1994). 
Reduced muscle tone during sleep: During sleep muscle tone is reduced throughout the body. 
Reduced diaphragm and accessory respiratory muscle tone contributes to the reduction in minute 
volume that has been recorded during sleep (Orem et al., 2002). The reduced tone in the upper airway 
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dilator muscles results in an increased resistance to airflow in the pharynx. This hypotonia can produce 
upper airway collapse in predisposed individuals as a result of negative inspiratory pressure 
generation in the thorax, and positive extra-luminal pressure, produced by gravitational forces, and 
adipose tissue. The critical collapsing pressure of the upper airway (termed Pcrit) is ultimately 
determined by the transmural pressure (Dempsey, 2010). 
Apnoeas caused by upper airway obstruction are terminated by an arousal from sleep that leads to 
increased tone in the airway dilator muscles and a return to waking-state ventilatory control; hence 
regular breathing. The physiological conditions that induced the airway obstruction return on 
resumption of sleep, and OSA patients can experience multiple cycles of sleep-apnoea throughout the 
night (Fig 1.2). 
1.2.2 The prevalence of OSA 
The prevalence of OSA appears to be rising. This is likely to be due to the aging population, and an 
obesity epidemic in developed countries. Both obesity and aging are high risk factors for OSA. This 
section describes the way in which the prevalence of OSA has increased over the past 20 years. 
The most widely quoted figures for the prevalence of OSA are taken from the Wisconsin Sleep Cohort 
(Young et al., 1993). During the period between 1988 and 1994 the prevalence of moderate-severe 
OSA (AHI ≥ 15 events/hour) in the Cohort was estimated to be 8.8% in males aged 30-70. By 
comparison, during the period between 2007 and 2010 the estimated prevalence had risen to 13%. 
OSA is less common in women, but a similar increase has occurred from 4% in the period between 
1988 and 1994, to 6% in the period between 2007 and 2010 (Young et al., 1993; Peppard et al., 2013). 
As mentioned above the most likely reason for the increasing prevalence of OSA is the increasing 
prevalence of obesity. In 1993, 15% of the UK adult population was obese (BMI >30 Kgm2). In 2011 
this had risen to 25% (Health and Social Care Information Centre; http://www.hscic.gov.uk). 
OSA is also more common with increasing age. The Wisconsin Sleep Cohort data showed that 10% of 
men aged 30-49.9 years had moderate-severe OSA, compared to 17% of men aged 50-70 years. This 
age distribution is even more pronounced in women where the prevalence increases from 3% in 30-
49.9 year olds, to 9% in women from 50-70 years. The increased prevalence of OSA in older people is 
supported by other epidemiological studies, which estimate the prevalence of OSA in people over 65 
years to be approximately 20%, with some estimates as high as 70% (Ancoli-Israel et al., 1989; Young 
et al., 2002b; Hader et al., 2005b). 
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The factors that contribute to the age-related increase in the prevalence of OSA include a reduction 
in pharyngeal muscle function (Worsnop et al., 2000b) and a more collapsible upper airway (Kirkness 
et al., 2008b). Age-related differences in upper airway structure include a decrease in the size of the 
upper airway lumen (Carlisle et al., 2014), associated with an age-related changes to the position of 
the hyoid bone (Pae et al., 2008). An increase in arousal frequency, has an associated change in the 
stability of breathing (Browne et al., 2003a). Perhaps the most important change is an increase in the 
prevalence of co-morbidities. For example, patients with chronic heart failure are more likely to have 
both obstructive and centrally mediated sleep apnoea (Vazir et al., 2007). 
1.2.3 The Sequelae of OSA 
OSA is known to impact multiple organ systems, and the most commonly investigated are 
cardiovascular and metabolic changes. However, other conditions as diverse as skin cancer, 
Alzheimer's disease and retinal dysfunction have been linked with OSA. This section will briefly outline 
the cardiovascular and metabolic effects of OSA. The association between OSA and brain function, 
which is the focus of this thesis will be covered in Section 1.3. 
Cardiovascular: The association between OSA and hypertension has been known for many years 
(Fletcher et al., 1985; Strohl et al., 1994; Bixler et al., 2000). Longitudinal data from the Wisconsin 
Sleep Cohort suggests that hypertension is a consequence of OSA, with a three fold increased risk of 
hypertension in OSA patients with severe disease (Peppard et al., 2000). OSA patients are also at 
increased risk of coronary artery disease and heart failure (Mooe et al., 1996; Mooe et al., 2001; 
Shahar et al., 2001). 
The mechanisms that lead to increased cardiovascular disease in OSA have been studied in both 
animal and human models. The difficulty in demonstrating causality is that both OSA and 
cardiovascular disease are linked with obesity. The most likely factors by which OSA (independent of 
obesity) causes cardiovascular disease are increased sympathetic nervous system activity, hypoxic and 
oxidative stress, systemic inflammation, and mechanical factors secondary to intrathoracic pressure 
oscillations, e.g. reduced left ventricular stroke volume, systemic arterial pressure, cardiac output and 
heart rate (Somers et al., 2008), (Drager et al., 2011). 
Metabolic: OSA is strongly associated with obesity and therefore as with cardiovascular disease, the 
extent to which there is an independent association between OSA and metabolic disease is debated. 
Current data appear to show a particular link with insulin resistance and type-2 diabetes mellitus 
(Ancoli-Israel et al., 1989; Strohl et al., 1994; Punjabi et al., 2002). Specifically the link with insulin 
resistance may be a combination of both central and visceral obesity, although sympathetic drive from 
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frequent arousals, intermittent hypoxia and sleep fragmentation may also play a role (Punjabi et al., 
2004; Spiegel et al., 2009). 
Additional metabolic factors have also been studied, including blood lipid levels (triglycerides, low 
density lipoproteins, non-high density lipoproteins and total cholesterol). The impact of OSA on 
triglycerides as a marker of cardiovascular disease has also been evaluated, with 2 months of 
treatment leading to a reduction in triglyceride and cholesterol levels (Phillips et al., 2011). Recent 
data from the UK show that diabetic patients with OSA are more likely to have diabetic retinopathy 
and neuropathy, and an ongoing treatment trial is investigating the role that reducing OSA could have 
on diabetic retinopathy (Harsch et al., 2004; Kosseifi et al., 2010; Mason et al., 2012; Rudrappa et al., 
2012). 
1.2.4 The Treatment of OSA 
There are many treatments for OSA and their application depends in part on the severity of the disease 
(Fig 1.4). For patients with mild disease modifying lifestyle (weight loss, stopping smoking, and 
cardiovascular exercise), increasing total sleeping time, and improving the sleeping environment (e.g. 
remove digital screens etc. from the bedroom) can help. Additionally, improving diet and reducing 
stimulants, such as caffeine, before bedtime is advisable. For patients who only have OSA when 
sleeping in the supine position, positional aids can help. Optimising medical management of co-
morbidities is another key part of treatment e.g. pain control, and optimising cardiorespiratory 
function. In patients with mild to moderate disease, oral mandibular advance devices are often 
helpful. The most commonly used treatment for OSA is positive airway pressure, which acts as a 
pneumatic splint blowing air into the upper airway and preventing collapse (Fig 1.5). There are 
different forms of pressure delivery, including continuous positive airway pressure (CPAP), 
autotitrating CPAP (auto-CPAP), bilevel ventilation and adaptive servoventilation (ASV). OSA is most 
effectively treated with CPAP, and this section will summarise the reasons why CPAP is considered the 
mainstay of treatment for patients with moderate to severe OSA. 
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Figure 1.4 Algorithm for the treatment of mild, moderate, and severe obstructive sleep apnoea (OSA). 
Upper airway resistance (UAR), cardiovascular disease (CVD). 
 
 
 
Figure 1.5 A patient using CPAP 
The recent National Institute for Health and Care Excellence (NICE) Health Technology Appraisal of the 
use of CPAP concluded that it was an efficacious and cost-effective treatment for OSA syndrome 
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(McDaid et al., 2009). The benefit of CPAP is measured in most trials as an improvement in sleepiness 
as measured by the Epworth Sleepiness Scale (ESS; See Chapter 2, Section 2.3.1). The ESS is a 
subjective measure of sleepiness and treatment with CPAP (versus conservative treatment) reduces 
sleepiness by approximately 2.7 points (95% confidence interval -3.45 to -1.96). The reduction in 
sleepiness is proportional to the severity of the disease and therefore patients with severe OSA often 
feel more relief of symptoms than those with mild disease. 
The cost of CPAP treatment is relatively cheap (compared to no treatment) per quality adjusted life 
year (QALY) gained at <£4,000 (McDaid et al., 2009). However, the majority of the cost is associated 
with a reduction in the incidence of cardiovascular disease, stroke, and road traffic accidents 
associated with sleepiness. Thus in patients who are not sleepy, and have a low cardiovascular and/or 
cerebrovascular risk CPAP may not be cost-effective. 
The effectiveness of CPAP therapy is also related to the adherence to treatment. Adherence to CPAP 
is estimated to range from 46% to 83%, with an average nightly usage of 2.39 hours per night in 
minimally symptomatic middle-aged OSA patients (Craig et al., 2012) and 2 hours 22 mins in older OSA 
patients at 12 months (McMillan et al., 2014). This is somewhat lower than the 4 hours per night on 
70% of nights which is commonly used as the benchmark for CPAP adherence, and less than the 
optimal outcomes achieved with a usage of at least 5 hours per night. Factors that impact CPAP 
compliance are shown in Table 1.1 (adapted from the Oxford Handbook of Medicine chapter 
submitted for publication). The percentage of patients who continue using their CPAP falls over time, 
e.g. from 84% at the end of the first year to 68% after 4 years, remaining at this level for a further 3 
years. The weighted average for studies that report discontinuation rates over 3 years was estimated 
to be 3.8% per annum 
  
22 
 
Table 1.1: Predictors of poor CPAP adherence include 
Patient characteristics – increased nasal resistance, depression 
Disease characteristics – either severe or mild minimally symptomatic disease 
Psychological or social – less self-efficacy, poor social support, limited disease or treatment 
knowledge 
Technical – lack of heated humidification and flexible pressure 
 
1.3   COGNITIVE FUNCTION AND OSTRUCTIVE SLEEP APNOEA 
There have been many studies of OSA and cognitive function. These have shown an association 
between OSA and a broad range of neurocognitive impairments (Bucks et al., 2013). A recent study by 
our group demonstrated deficits in verbal memory (Twigg et al., 2010), while other studies have found 
deficits in spatial memory (Varga et al., 2014) (Daurat et al., 2008), reaction time (Bedard et al., 1991; 
Bedard et al., 1993) and numerical memory (Verstraeten et al., 2004). Even in cognitive tests where no 
impairment has been detected, functional imaging has demonstrated that sleepy OSA patients utilise 
spare capacity in brain regions not utilised by healthy controls to achieve normal cognitive function 
(Ayalon et al., 2006). However, despite these data, the impact of OSA on cognitive function remains 
controversial. Indeed, it has recently been argued that there is only a weak correlation between 
(subjective) cognitive complaints, and objective cognitive function in patients with OSA (Vaessen et al., 
2014). The wide variation in the reported cognitive dysfunction of patients with moderate to severe 
OSA was the starting point for the studies reported in Chapters 3-5 of this thesis. 
1.3.1  Impaired Cognitive function in OSA 
A recent meta-analysis determined that deficits in attention/vigilance, delayed long-term visual and 
verbal memory, visuospatial/constructional abilities and executive dysfunction have been consistently 
reported in patients with OSA (Twigg et al., 2010; Bucks et al., 2013). The cognitive impairment 
appears to be associated with the severity of hypoxaemia, while the attention and vigilance 
dysfunction is more likely to be associated with the degree of sleep fragmentation (Bucks et al., 2013). 
Working memory, short-term memory, and global cognitive functioning and language ability appear 
to be largely unaffected by OSA (Bucks et al., 2013). 
There are several possible explanations for the wide range of results seen in these studies: The 
subjective tests used may not be specific enough to detect accurately the cognitive deficits (see 
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Chapter 2, Section 2.4 for a detailed explanation of the cognitive tests used in this thesis), indeed the 
objective tests used are frequently designed to detect deficits in patients with brain-injuries, and 
therefore may not be able to capture the milder impairments that occur in OSA (Vaessen et al., 2014). 
Similarly, one day (or night) of testing provides only a ‘snapshot’ of the patient’s ability. This kind of 
testing is unable to take account of time-dependent factors, such as fluctuation over time and various 
circadian influences. Moreover, cognitive domains frequently involve more than one construct. 
Therefore only carefully deconstructed analyses of the different cognitive test results can accurately 
assess patient deficits (Olaithe et al., 2014). Finally, the cognitive dysfunction may be a sign of 
psychological distress, rather than impairment (Pullens et al., 2010; Vaessen et al., 2014). Of note, 
cognitive reserve and genetic vulnerability (e.g. apolipoprotein e4 genotype) are likely to be factors in 
the susceptibility to cognitive dysfunction (Rosenzweig et al., 2013c; Olaithe et al., 2014; Rosenzweig 
et al., 2014). Some other important factors considered during the design of the studies presented in 
this thesis were the duration of exposure to the disease, the role of the blood-brain barrier and co-
morbidities such as hypertension, metabolic dysfunction and systemic inflammation. 
1.3.2 Treatment of Cognitive Function in OSA 
Both pharmacological and non-pharmacological treatments for OSA have been shown to improve 
cognitive function in patient with OSA. Several meta-analyses suggest that CPAP treatment reduces 
sleepiness and improves mood, and that these changes are associated with improvements in objective 
cognitive functioning (Giles et al., 2006; Marshall et al., 2006; Kylstra et al., 2013; Vaessen et al., 2014). 
Although less successful, drugs such as donepezil, phylostigmine, and fluticasone have also been used 
to try to improve cognitive outcomes in treated OSA patients (Kohler et al., 2009; Mason et al., 2013). 
Of interest for the studies presented in this thesis, CPAP treatment also appears to reverse some, but 
not all, neuroanatomical changes. Specifically the study by Canessa et al, 2011 showed that 3 months 
of CPAP treatment improved cognitive function in several domains and that these improvements were 
correlated to grey matter volume increases in frontal and hippocampal regions (Canessa et al., 2011). 
Another recent study showed significant improvements involving memory, attention, and executive 
functioning that correlated with white matter changes after 12 months of treatment with CPAP 
(Castronovo et al., 2014). However, in these studies not all areas showed complete reversal of tissue 
damage, or deficits in cognition, suggesting that initiation of prolonged treatment may be needed as 
early as possible in the disease process (Kushida et al., 2012; Prilipko et al., 2012; Ferini-Strambi et al., 
2013; Yaffe et al., 2014). 
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To investigate the effect of disease duration on cognitive function, studies have been carried out 
looking into the cognitive performance and effects of treatment in children with OSA (Gozal, 1998; 
Biggs et al., 2014). In a recent study of children with sleep disordered breathing (SDB), followed-up for 
four years, treatment led to improvements in several aspects of neurocognition, collectively 
categorised as performance IQ (Biggs et al., 2014). 
Performance IQ represents fluid intelligence and is reflective of incidental learning. It describes the 
subject’s ability to adapt to new situations (Cattell, 1967). In the study by Biggs et al, improvements 
were recorded in tasks associated with spatial visualisation, visuo-motor coordination, abstract 
thought and non-verbal fluid reasoning (Biggs et al., 2014). However, overall improvements in the 
academic ability or behaviour were less clear. Furthermore, worsening of verbal IQ, which, unlike 
performance IQ, is more likely to be affected by formal education and learning experiences, was noted 
in a treated group (Biggs et al., 2014). No conclusive explanation for this finding was provided, and no 
statistically significant association between the reduction in verbal IQ performance and treatment was 
demonstrated (Biggs et al., 2014). 
Conversely, in the seminal study by Gozal in 1998, younger children with SDB were followed for 12 
months after treatment and significant improvements in academic performance were recorded 
(Gozal, 1998). The different neurodevelopmental ages of children, and different test parameters used 
may account for the differences in findings between the two groups. Nonetheless, similarities may be 
emerging from these studies of children and earlier work. Specifically, associations between 
performance IQ and slow wave activity (SWA) during the non-rapid eye movement (NREM) sleep 
(Biggs et al., 2012; Biggs et al., 2014). 
In healthy adults, sleep progresses through NREM stages N1 to N3 followed by a period of REM sleep 
occurring approximately 60- 90 minutes into sleep (Vyazovskiy & Delogu, 2014). It has been argued 
that cognitive improvements in treated OSA patients may reflect increased stability of brain activity 
during sleep, allowing crucial synaptic repair and maintenance to occur during SWA, and counteracting 
the toxic effects of OSA mediated by arousal and hypoxia (Neubauer & Fink, 2009; Biggs et al., 2014). 
This argument is supported by findings showing that sleep presents a crucial period during which the 
brain can restore cellular homeostasis (Fig 1.6), increase signal to noise ratio, and reinforce neuronal 
circuitry for subsequent cognitive processing demands (Poe et al., 2010; Abel et al., 2013; Tononi & 
Cirelli, 2014). 
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Figure 1.6: “Sleep is the price we pay for [neural] plasticity” Tononi & Cirelli 2014. Figure shows neural 
connections in a fruit fly (left) following sleep, enriched wakefulness, sleep after enriched wakefulness 
and wake after enriched wakefulness with no sleep. Note the smallest number of synapses occur 
following sleep, and the most following sleep deprivation. New learning occurs during wakefulness via 
synaptic potentiation. Neurones strengthen synapses during enriched wakefulness, while interacting 
with the environment e.g. fear conditioning, cue-reward learning etc. Neurones renormalize synapses 
in sleep when the brain is off line; synapses have a high energy cost and neural ‘space’ may be reduce 
if sleep does not occur. 
 
1.3.3 Sleep Deprivation and Cognitive Function in OSA 
Sleep alters the molecular signalling pathways that regulate synaptic strength (Fig 1.6), plasticity-
related gene expression and protein translation (Abel et al., 2013). Moreover, sleep deprivation can 
impair neuronal excitability, decrease myelination and lead to cellular oxidative stress and misfolding 
of cellular proteins (Abel et al., 2013; Picchioni et al., 2014). 
The frequent arousals and ensuing fragmented sleep that occur in OSA, have been shown to impact 
on cognitive function the following day, in a manner similar to that of total sleep deprivation 
(Daulatzai, 2013). Studies of the effects of sleep deprivation on cognition in the general population 
suggest comparable cognitive impairments to those seen in OSA (Killgore, 2010). Furthermore, an 
association has been shown between excessive daytime somnolence and cognitive impairment and 
an increased risk of cognitive decline and dementia (Yaffe et al., 2014). In a prospective cohort study 
(The Honolulu-Asia Aging Study), lower nocturnal oxygenation and a reduction in SWA NREM sleep 
were associated with the development of micro-infarcts and brain atrophy. Conversely, men with 
longer SWA sleep showed slower cognitive decline (Gelber et al., 2014).  
The impact of OSA on selected sleep stages may be particularly important, as each sleep stage is 
associated with its own functional learning and memory processes (Poe et al., 2010). In OSA patients, 
stage N2 NREM sleep has been shown to increase, while stages N1, N3 and REM sleep decrease Fig 
1.7 (Andreou et al., 2014). 
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Figure 1.7: Overnight sleep patterns (hypnogram), obtained from electroencephalography, illustrating 
sleep cycles in a young healthy person (Top panel). Note that NREM is the first sleep, and the first REM 
sleep occurs after approximately 90 minutes; throughout the night there are occasional brief arousals 
from sleep. The Bottom Panel illustrates sleep cycles in an OSA patient.  Note that throughout the 
night there are frequent, brief arousal from sleep with a reduction in both NREM stage 3 and REM 
sleep. W: wake; R: REM sleep (marked in blue); 1, 2, 3: NREM stage 1, 2 and 3 sleep. 
 
The consequences of sleep fragmentation in OSA are difficult to assess. In one study of mild OSA, 
where sleep fragmentation did not significantly reduce the scoring of N3 Sleep, the exponential decay 
function of SWA was demonstrated as significantly slower in patients than in controls (Ondze et al., 
2003). This was due to the more even distribution of SWA throughout the night. These results show 
that mild sleep fragmentation can alter the dynamics of SWA, without decreasing significantly the 
amounts of SWA and REM sleep. This means that to fully understand the impact of sleep deprivation 
in OSA it may be necessary to perform SWA decay analysis (Ondze et al., 2003). In the same study, a 
decrease of spindle activity was observed in N2 and N3 which was not attributable to an increase of 
SWA (Ondze et al., 2003; Schonwald et al., 2012). Such a reduction in total spindle density has also 
been reported in sleep maintenance insomnia, and is likely to be related to sleep fragmentation 
(Ondze et al., 2003; Schonwald et al., 2012). 
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REM Sleep: Traditionally, obstructive events during NREM sleep were viewed as associated with 
greater cognitive deficits or impaired quality of life, whilst REM sleep events were shown to be 
associated with greater sympathetic activity, hypertension and cardiovascular instability in patients 
with OSA (Mokhlesi et al., 2014) (Mokhlesi & Punjabi, 2012). Recently, a role for fragmented REM 
sleep in spatial navigational memory problems in OSA patients was suggested (Varga et al., 2014). 
During this study, patients spent two different nights in the laboratory, during which they performed 
timed trials, before and after sleep, on one of two unique 3D spatial mazes (Varga et al., 2014). The 
normal consolidation of sleep was achieved with use of therapeutic CPAP throughout the first night, 
whereas during the second night CPAP was reduced only during the REM stages. Here, patients 
showed improvements in maze performance after a night of normal sleep, and those improvements 
were significantly reduced following a night of REM disruption without changes in psychomotor 
vigilance. Cognitive improvements were significantly positively correlated with the mean REM run 
duration across both sleep conditions (Varga et al., 2014).  
In some OSA patients, reduction of REM sleep can lead to dissociation of REM traits to other sleep 
stages, further impacting on critical sleep windows for memory formation and consolidation (Poe et 
al., 2010). Of particular note, several studies have now demonstrated that, if high homeostatic 
demands are not fully met during sleep,  microsleeps can occur in highly active regions of the brain  
during the subsequent wake period (Vyazovskiy & Delogu, 2014). This can lead to the concomitant 
disability of that region (Tononi & Cirelli, 2014; Vyazovskiy & Delogu, 2014). To what extent this takes 
place in OSA patients, and whether this also contributes to attention/vigilance dysfunction and the 
higher rate of road traffic accidents seen in OSA patients has yet to be fully understood. Previously 
reports of retarded SWA decay through the night in even mild OSA patients further supports the 
notion of non-restorative sleep in OSA (Ondze et al., 2003) . 
Sleep Spindles: Intriguingly, in a study of spindle frequency changes in OSA, it has been shown that, 
unlike healthy controls, OSA patients continued displaying a significant proportion of slow spindles in 
frontal, central and parietal regions during the night. This may suggest that deregulated spindle 
formation contributes to cognitive deficits in OSA patients (Schonwald et al., 2012). In another study, 
sleep architecture of patients with mild OSA showed a high degree of sleep fragmentation resulting in 
a different time course of SWA and a decreased sleep spindle index when compared to controls 
(Ondze et al., 2003). 
Taken together, these studies further highlight the possible role for OSA brain injury in the 
acceleration, or even initiation, of cognitive decline especially in older people (Sforza & Roche, 2012; 
Daulatzai, 2013; Pan & Kastin, 2014; Yaffe et al., 2014). 
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1.4   ISCHAEMIC CONDITIONING AND NEURO-INFLAMMATION IN OSA  
In OSA, repetitive occlusions of the upper airways lead to intermittent hypoxia and recurrent 
hypoxaemia, typically characterized by short cycles of hypoxia and reoxygenation (Almendros et al., 
2014). These cycles can lead to either adaptive or maladaptive processes (Almendros et al., 2014) and 
the outcome will vary depending on the dynamic interplay between the specific type and amount of 
reactive oxygen/nitrogen species produced, their duration and frequency, the intracellular 
localization, and the micro-environmental antioxidant activity (Lavie, 2014). Additional interplay 
depends on factors such as the genetic makeup, nutrition and other lifestyle related variables, which 
all affect the redox status (see also (Almendros et al., 2014; Lavie, 2014)). A variety of studies to date 
suggest that severity of hypoxia, its duration, and cycle frequency, are fundamental determinants of 
outcomes (Ayalon et al., 2010). For example, it has generally been acknowledged that short, mild, and 
lower cycle frequency may generate beneficial and adaptive responses in brain, such as ischaemic 
preconditioning (Almendros et al., 2014). Conversely, chronic moderate-to-severe, and high frequency 
intermittent hypoxia can induce maladaptive disruption of homeostatic mechanisms, leading to 
dysfunction and sterile neuroinflammation (Almendros et al., 2014; Lavie, 2014).  
1.4.1 Ischaemic preconditioning 
Ischaemic preconditioning represents a generalized adaptation to ischaemia by a variety of cells (Lavie 
& Lavie, 2006; Dirnagl et al., 2009). In OSA, induction of ischaemic preconditioning is thought to be 
due to the activation of several gene programs, including the hypoxia inducible factor-1, vascular 
endothelial growth factor, erythropoietin, atrial natriuretic peptide and brain derived neurotrophic 
factor (Brzecka, 2005; Nanduri et al., 2008).Various end-mechanisms and pathways have been shown 
to play a role, including that of long-term facilitation of diaphragmatic  motor output, chemo-reflex 
activation, vascular remodelling, neo-angiogenesis, productive autophagy, reactive gliosis, various 
synaptic alterations. Modulation of adult hippocampal neurogenesis has also been suggested (Haddad 
& Yu, 2009; Aviles-Reyes et al., 2010; Tsai et al., 2011; Papadakis et al., 2013; Tsai et al., 2013; Lavie, 
2014). 
CPAP treatment of OSA has been shown partially to reverse the damage in the hippocampus, and to 
ameliorate some of the associated cognitive deficits, possibly also by modulating adult neurogenesis 
(Canessa et al., 2011). It is proposed that at any given time ongoing maladaptive neuro-inflammatory 
processes probably exist alongside adaptive mechanisms of increased brain plasticity and ischaemic 
preconditioning (Ferriero, 2005; Lledo et al., 2006; Dirnagl et al., 2009; Seki, 2011; Rosenzweig et al., 
2013a). In a recent study that compared the cognitive performance of patients with high and low 
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hypoxemia after controlling for demographic factors and other aspects of OSA severity, an unexpected 
advantage of higher hypoxemia on memory was demonstrated in a carefully matched clinical cohort 
(Hoth et al., 2013).  
Another powerful central neuroprotective adaptive mechanism for ischaemic events was 
demonstrated following the activation of the intrinsic neurons of the cerebellar fastigial nucleus (Reis 
et al., 1997). Neurostimulation of these nuclei appears to provide protective reduction in excitability 
of cortical neurons during the subsequent ischaemic episodes, and to lead to reduced 
immunoreactivity of cerebral microvessels by down-regulating their production of intracellular cell 
adhesion molecule (ICAM-1) and consequently preventing the release of pro-inflammatory cytokines 
(Rosenzweig et al., 2014). The compensatory entraining of the cerebellum by hypertrophic 
hippocampi may also occur in younger patients with mild OSA (See Chapter 3). 
Although there are no direct monosynaptic anatomical connections between hippocampi and 
cerebellum, their connectivity is thought to be important for the control of movement under states of 
heightened emotion and novel conditions, and for associative learning. Of note, failed adaptation of 
cerebellar networks to injury was shown to lead to cognitive deficits and hyperactivity, distractibility, 
ruminative behaviour, dysphoria and depression in some patients (Rosenzweig et al., 2014). Several 
studies also suggest that, under certain conditions, intermittent hypoxia can increase immune 
defences without exacerbating inflammation (Almendros et al., 2014; Lavie, 2014). Moreover, in 
animals, short-lasting hypoxic exposures mimicking OSA were associated with recruitment of bone-
marrow derived pluripotent stem cells, which exhibited up-regulation of stem cell differentiation 
pathways, particularly involving central nervous development and angiogenesis (Almendros et al., 
2014). 
1.4.2 Neuro-inflammation 
Intermittent hypoxia can lead to maladaptive effects, including neuro-inflammation. Although the 
exact neurocellular sources for associated processes are still incompletely understood, it is likely that 
activation of astroglia is important (Dale et al., 2014; Lavie, 2014). In addition, the oligodendrocytes, 
myelin-producing cells of the CNS, were shown to be selectively sensitive to hypoxia and sleep 
fragmentation (Rosenzweig et al., 2012; Bellesi et al., 2013). The subsequent loss of buffering 
functions can ultimately contribute to pathological processes, such as increased glial proliferation and 
microglial activation (Dale et al., 2014). Astroglial and microglial cells play critical roles in regional 
blood flow regulation and inflammatory processes in the brain, as well as critical coordination of 
bioenergetics through lactate transport (Dale et al., 2014). Under normal conditions, microglia in the 
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healthy CNS exhibit a surveillance phenotype that synthesizes and releases neuroprotective 
growth/trophic factors (Dale et al., 2014). However, severe and prolonged hypoxia can activate 
microglia toward a toxic, pro-inflammatory phenotype that triggers pathology, including change in 
hippocampal structure, impaired synaptic plasticity, and cognitive impairment (Dale et al., 2014) (See 
Chapter 5). Neuro-inflammation has been shown independently to raise the brain's sensitivity to 
stress, resulting in stress-related neuropsychiatric disorders, such as anxiety and depression (Skaper 
et al., 2014). 
Dynamic changes in transcription of inflammatory genes were demonstrated following exposure to 
intermittent hypoxia, with most inflammatory markers increasing over time (Dale et al., 2014). 
Increased concentrations of prostaglandin E2 in neural tissue have also been demonstrated in 
hippocampal and cortical regions accompanied by lipid peroxidation of polyunsaturated fatty acids 
(Dale et al., 2014). Similarly, it was shown that increased carbonylation- and nitrosylation-induced 
oxidative injury emerges in susceptible brain regions and promotes increased daytime somnolence 
(Dale et al., 2014; Lavie, 2014). Recently, toll-like receptor 4 (TLR4) expression and activity was 
demonstrated to be increased in monocytes of patients with OSA (Unnikrishnan et al., 2014). 
Expression of TLR4 was also demonstrated in the microglia of the cortex and brainstem after chronic 
intermittent hypoxia where it was postulated to play region specific and differential adaptive or 
maladaptive role (Unnikrishnan et al., 2014). This finding is of particular interest since TLR4 has also 
been strongly implicated in several inflammatory and neurodegenerative disorders, including vascular 
dementia and Alzheimer’s disease (Unnikrishnan et al., 2014). In line with this, in cognitively healthy 
adults, intermittent hypoxia was correlated with increases in phosphorylated and total tau and 
amyloidᵝ1-42 concentrations in cerebral spinal fluid, which are key components of Alzheimer’s 
pathology (Yaffe et al., 2014). Similarly, cerebral amyloidogenesis and tau phosphorylation along with 
neuronal degeneration and axonal dysfunction were shown in the cortex and brainstems of animals 
exposed to intermittent hypoxia (see Chapter 5) (Daulatzai, 2013). 
Taken together, these findings support the role for neuro-inflammatory processes in cognitive and 
emotional deficits of OSA patients. They further suggest a close association between hypoxaemia- 
induced maladaptive processes and dementia. 
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1.5. DESCRIPTION AND STRUCTURE OF THESIS 
The primary aim of this thesis is to investigate the effects of OSA on brain structure. The thesis will 
also investigate whether treatment of OSA with CPAP leads to resolution of any changes in brain 
structure, possibly mediated by ischaemic preconditioning. Finally the thesis will investigate whether 
these changes in brain structure are associated with corresponding changes in cognitive function. 
The general methods used for all the studies in this thesis will be described in Chapter 2. Additional 
background to the individual studies will be presented in each chapter, with further details of study 
protocols, data analysis and statistical analyses where necessary. 
In Chapter 3 I will describe the reanalysis of brain imaging data gathered previously by the group using 
more modern techniques. The aim of this study was to investigate the effect of intermittent hypoxia 
on brain structure in OSA patients. I was interested in brain hypertrophy, suggestive of ischaemic 
preconditioning, as well as the hypotrophy demonstrated in other studies. 
In Chapter 4 I will describe a randomised controlled trial of CPAP in OSA. Brain structure and cognitive 
function were measured in younger people newly diagnosed with OSA before and after randomisation 
to CPAP or best supportive care. This aim of this study was to investigate the association of brain 
structural changes with cognitive dysfunction in OSA and to investigate whether these changes were 
reversible. 
Chapter 5 will describe an analysis of brain structure in older people with OSA before and after 
randomisation to CPAP. The aim of this study was to investigate whether neuroplasticity still existed 
in older patients with OSA, or whether any brain structural changes caused by OSA were irreversible. 
In Chapter 6 the results of the studies presented in this thesis will be discussed, with some suggestions 
as to how the results, and areas of uncertainty identified during this research, could be developed in 
the future 
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CHAPTER 2 
General Methods 
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2.1  PARTICIPANT AND LABORATORY INFORMATION 
OSA patients were recruited from The Royal Brompton (Chapters. 3, 4 and 5), Harefield (Chapter 4) 
and Charing Cross (Chapter 3) Hospitals and Queen Elizabeth Hospital, Woolwich (Chapter 4). Controls 
were recruited from the Healthy Volunteers Database in the Academic Department of Sleep and 
Ventilation and from hospital staff at The Royal Brompton Hospital. Sleep studies were performed at 
The Royal Brompton as part of routine clinical practice. In addition, research nocturnal 
polysomnography was carried out (Chapter 4) in the NIHR Respiratory Biomedical Research Unit (BRU) 
at The Royal Brompton Hospital. MRI scans were performed at both The Royal Brompton Hospital 
(Chapter 4), and Charring Cross Hospital (Chapter 3 & 5). In the study presented in Chapter 4, I was 
the first investigator to use the Respiratory BRU Clinical Research Facility for overnight studies and 
helped to develop the pathway for future overnight studies. The study in Chapter 4 was also the first 
collaboration between the Respiratory BRU and the Cardiology BRU at The Royal Brompton and the 
first study to use the Cardiology BRU MRI scanners to perform brain imaging. I set up this 
collaboration, and arranged the sharing of knowledge and expertise between our previous imaging 
collaborators and the physicists and radiographers at The Royal Brompton to ensure the correct MRI 
sequences were used and the images obtained were of appropriate quality.  I also set up two new 
collaborations, to recruit patients from Harefield Hospital and Queen Elizabeth Hospital, Woolwich to 
Royal Brompton sleep research projects for the first time. 
 
All studies were carried out with Research Ethics Committee approval, and all participants gave 
written informed consent. Note, the IRAS ethical approval numbers are given in each experimental 
chapter. 
 
2.2 NOCTURNAL POLYSOMNOGRAPHY 
Polysomnography was performed in all OSA patients using the SOMNOscreen system (SOMNOmedics 
GmBH, Germany). This system allows data to be was transmitted wirelessly in real time to a computer, 
ensuring that the patient has as comfortable a night’s sleep as possible (Fig 2.1). 
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Figure 2.1: Studies presented in this Thesis used nocturnal polysomnogram to diagnose the severity 
of the OSA. Note that the patient is able to move freely as the system used is wireless. 
2.2.1 Assessment of sleep : EEG, EOG and EMG 
Electroencephalogram (EEG), electro-oculogram (EOG) and surface electromyogram (EMG) are used 
to monitor sleep and wake, using standard sleep scoring criteria (Reschtschaffen, 1968). EEG was 
measured using 10mm gold cup electrodes (Grass technologies, Rhode Island, USA). The electrodes 
were sited according to the International ten twenty EEG electrode system. This system uses the 
nasion and inion as reference points, with EEG electrodes placed at increments of 10 or 20% along 
transverse and sagittal lines linking these landmarks. Electrodes were placed in the C3 and C4 
positions, with a common reference electrode in the Cz position (Fig 2.2). 
The electrode positions were marked with a chinagraph pencil and the site was cleaned with an 
abrasive paste (Nuprep, Weaver and Company, Colorado, USA) and an alcohol soaked swab. This 
process reduced the electrical impedance between the electrode and the skin. It also helped the 
attachment of the electrode. The gold cup electrodes were then filled with conducting paste (Ten20 
conductive paste, Weaver and Company, 
Colorado, USA ) and fixed in place with 
adhesive (Collodion, SLE Ltd., 
South Croydon, UK). Reference 
electrodes were placed over left and 
right mastoid processes (A1 and A2 
respectively) and a ground electrode was 
placed on the centre of the forehead 
(Fig 2.2).  
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Figure 2.2. A view of the head showing the electrode positions of the international ten twenty system 
for recording of sleep using electroencephalography (EEG). (Figures adapted from  Malmivo & Plonsey. 
Bioelectromagnetism: Principles and Applications of Bioelectric and Biomagnetic Fields. New York: 
Oxford University Press; 1995)  
 
Self-adhesive electrodes were used to measure EOG activity. These were placed 1 cm lateral and 
superior to the right outer canthus, and 1 cm lateral and inferior to the left outer canthus and 
referenced to the A1 mastoid electrode. By placing the EOG electrodes asymmetrically conjugate 
vertical eye movements, which produce opposing deflections in the right and left EOG signals, can be 
distinguished from electrode artefact or high voltage which produce in-phase deflections in both EOG 
signals. Self-adhesive electrodes were also used to record EMG activity. The skin was prepared as for 
the EEG and electrodes were positioned 2 cm posterior to the inferior edge of the mandible, and 2 cm 
to either side of the midline. 
After application of all electrodes, an impedance test was performed to ensure all electrodes had a 
low resistance for optimal detection of brain electrical activity. An impedance of <10,000 Ohms was 
considered acceptable, and where this was exceeded, further conducting paste was added to gold cup 
electrodes, or the electrode was replaced until impedance was satisfactory. 
The EEG and EOG signals were digitally sampled at a rate of 128 Hz, whilst the EMG signals were 
sampled at a rate of 256 Hz (Silber et al., 2007). The signals were processed by differential amplifiers 
to generate a conventional EEG montage (C3/A2; C4/A1, Right EOG/A1 and Left EOG/A1) for sleep 
scoring (Reschtschaffen, 1968). Conventional filter settings (High pass filter: 0.2 Hz; low pass filter: 35 
Hz) were applied to the differential amplifier output to remove signals outside of the frequencies of 
interest.   
2.2.2  Measurement of airflow using nasal pressure transducer 
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Airflow from the nose and mouth was monitored using a ‘nasal pressure’ signal, generated by changes 
in pressure at the nares. The pressure changes were measured by a nasal cannula (Embla, Colorado, 
USA) connected to a differential pressure transducer that was referenced to atmospheric pressure. 
The voltage output of the transducer was proportional to the pressure change across a membrane 
located within the transducer. 
The measurement of nasal pressure provides a semi-quantitative measure of the velocity of air passing 
through the nostrils (Fig 2.3). However, because the airflow is most commonly non-linear, nasal 
pressure overestimates apnoeas compared to other sensors (Redline et al., 2007). For example, if the 
amplitude of the nasal pressure signal falls below 10% (the commonly used criteria to score apnoea) 
when nasal airflow decreases to 30%. The Bernouilli equation states that the velocity of a gas is 
proportional to the square root of the gas pressure. Therefore, the nasal pressure signal is equivalent 
to the square of the airflow; for example, when nasal airflow decreases to 70% of baseline, the nasal 
pressure will decrease to 49%. It has been suggested that a square root transformation of the nasal 
pressure signal could be used in this case. However, in practice this is not often used. 
The within-breath shape of the nasal pressure airflow signal can also provide information about the 
occurrence of airflow limitation that does not fulfil the requirements to be scored as apnoeas or 
hypopnoeas (Fig 2.3). 
 
Figure 2.3: Nasal airflow, respiratory effort and oxygen saturation (SpO2) measured during sleep in a 
health person (left) and a patient with airflow limitation (right). Notice the flattened inspiratory airflow 
profile (green) in the patient with flow imitation, compared to the  healthy subject. 
 
2.2.3 Measurement of respiratory effort using respiratory inductance 
plethysmography 
Respiratory effort was measured by respiratory inductance plethysmography. This requires placement 
of a belt around the upper chest and a further belt around the abdomen, midway between the inferior 
ribs and the iliac crest (Fig 2.1). The belts were sized according to patient girth and were fastened with 
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Velcro. To ensure the belts did not become displaced during the sleep study they were further secured 
with tape. 
The respiratory inductance plethysmography bands measure changes in current, caused by an 
alteration in cross sectional area enclosed by a wire. A magnetic field is created by passing alternating 
current through a thin zigzagging wire which has been sewn into the RIP belt (Sleepsense, SLP Inc., 
Illinois, USA). This magnetic field is affected by changes in the cross-sectional area enclosed by the 
wire and this, in turn, alters the frequency of the current. The change in current can be measured, 
which provides a metric of respiratory and abdominal expansion during inspiration as shown in Fig 
2.3. 
 
 
2.2.4 Measurement of arterial oxygen saturation using pulse oximetry 
Finger pulse oximetry (Nonin 8000 Softsensor, Nonin, Minnesota, USA) was used to measure 
haemoglobin oxygen saturation. This measurement represents the average oxygen saturation of 
haemoglobin. It relies on the principle that the light absorption characteristics of haemoglobin are 
altered by the binding of oxygen. One arm of the clip contains LEDs that emit light at red (660nm) and 
infrared (910nm) wavelengths. Light transmitted through the finger is detected by a photodetector 
on the other arm of the clip. The absorption of light by blood constituents can be determined from 
changes in the quantity of transmitted light occurring during fluctuations in arterial volume with each 
cardiac cycle. The ratio of red and infrared light absorbed during these pulsatile fluctuations is used to 
calculate the oxygen saturation of haemoglobin. The oxygen saturation is then displayed as a moving 
time average as shown in Fig 2.3. 
2.2.5 Measurement of heart rate using ECG 
Heart rate was measured by placing ECG electrodes on the skin below each clavicle and below the 
lower left ribcage. 
2.2.6 Measurement of leg movement using EMG 
During sleep phasic limb movements (called Periodic limb movements [PLM]} can disrupt sleep in a 
similar way to OSA. Therefore, to differentiate between sleep disruption caused by occlusion of the 
upper airway, and that caused by PLM, EMG of the anterior tibialis muscle is monitored, and phasic 
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bursts of activity are scored. If more than 4 consecutive limb movements are noted, separated by not 
less than 5 seconds, but not more than 90 seconds the patients is said to have PLM. Limb movements 
can also occur during an arousal from sleep at the end of an apnoea/hypopnoea. Therefore, if the 
increase in anterior tibialis EMG activity occurs within 0.5 seconds of a respiratory event it is NOT 
scored as a limb movement. The PLM index is calculated as the mean number of PLMs per hour of 
sleep. 
 
2.3 ASSESSMENT OF SLEEPINESS 
One of the most common symptoms of OSA is excessive daytime sleepiness. The measurement of 
sleepiness is difficult. Subjective measurements, such as the commonly used ESS, are influenced by 
factors such as motivation, and objective measurements are often complex and time consuming. In 
this thesis, therefore, sleepiness has been measured subjectively using the ESS.  
2.3.1 Epworth Sleepiness Scale 
The Epworth Sleepiness Scale (Johns, 1991) is a widely used, validated questionnaire that assesses 
daytime sleepiness. The Epworth scale asks subjects to rank how likely, on average, “in recent times” 
they are to doze in 8 different situations. Each situation is given a mark out of 3 depending on how 
likely the subject is to doze in that situation (0 = never 1 = slight chance, 2 = moderate chance, 3 = high 
chance). The score for each situation is added to give a total out of 24. A total score of 10 or more 
indicates excessive daytime sleepiness. 
Although it was designed to be self-administered, a recent study found that 33% of patients made 
errors and 23% required assistance when completing the Epworth Sleepiness Scale for the first time. 
Even among patient who had used the Epworth scale previously, 16% made errors. Furthermore 4% 
of patients were unable to complete the form because of poor reading skills or because they did not 
have their glasses with them (Ghiassi et al., 2011). Another criticism is that ESS scores do not correlate 
(Furuta et al., 1999) or correlate only weakly with objective measures of sleepiness such as the 
multiple sleep latency test (MSLT). 
Despite these criticisms the ESS is widely used around the world. As well as the English language 
version, it has been translated into and validated in numerous other languages including: Croatian, 
French, German, Greek, Italian, Japanese, Korean, Mandarin, Norwegian, Portuguese, Serbian, 
Spanish, Thai and Turkish and a pictorial version has recently been validated (Drakatos et al., 2015). It 
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has even been argued that it is a better discriminator of excessive daytime sleepiness than the MSLT 
or the maintenance of wakefulness test (MWT) (Johns, 1991). 
 
2.4 ASSESSMENT OF COGNITIVE FUNCTION 
In Chapter 1 the relationship between OSA and cognitive function was reviewed, with a discussion of 
the possible mechanisms that may cause cognitive dysfunction in patients with OSA. In Chapter 2, I 
will review the cognitive tests used in the experimental Chapters 3-5. The tests were selected based 
on the results of previous studies carried out by the Sleep Group at the Royal Brompton Hospital (Fig 
2.4). A further discussion of the changes in brain morphology and function that may lead to the 
cognitive impairment is given in Chapter 3, Section 3.2. 
. 
 
 
 
 
 
 
 
 
 
Figure 2.4: This diagram shows the cognitive testing battery examining different aspects of memory 
and attention used in the studies of (Twigg et al., 2010). The battery was designed in consultation with 
Dr Kim Graham, MRC Cognition and Brain Sciences Unit, Cambridge. Each test was selected to examine 
aspects of long-term memory (semantic and episodic) and working memory. Episodic memory tests 
was further divided into verbal and visual tests. Two aspects of working memory were included in the 
battery, specifically maintenance of working memory and dual task performance. Several tests of 
attention were included in order to cover the different aspects of attention. 
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2.4.1 Logical Memory 
The Logical Memory test (WMS III, Harcourt, UK) is a validated test of verbal episodic memory. The 
different components of the test allow assessment of different subsets of episodic memory such as 
recognition memory, immediate recall and delayed recall. Two short stories are read to the subject. 
After each story is read the subject is asked to repeat the story, using as close to the same words as 
he can remember (immediate recall). One point is awarded for each unit of the story correctly 
repeated according to criteria supplied with the test. The subject is asked to repeat the 2 stories a 
second time 35 minutes after they were read (delayed recall). The same scoring system is used. 
Immediately following this second repetition the subject is asked a series of true-false questions about 
the stories (recognition memory). One mark is scored for each correct answer. 
2.4.2 Trail Making 
This is one of the most widely used neuropsychological tests and is included in most 
neuropsychological panels. TMT provides information on visual conceptual and visuo-motor tracking, 
motor speed, attention and executive functions. It consists of two parts, A and B. TMT – A is a dot-to-
dot in which circles containing the numbers 1 to 25 must be joined in numerical order by a line.  In 
TMT – B the circles contain either a number (1 to 12) or a letter (A to L). The aim is to join the circles 
in numerical and alphabetical order, alternating between letters and numbers (e.g. 1, A, 2, B, 3, C, 4, 
D etc.). The time taken to complete the tests is measured. Younger subjects and those with more years 
of education complete the test in less time than older subjects and those with fewer years of 
education, although normative data is available (Tombaugh, 2004). Most subjects complete the test 
in less than 300 seconds (Reitan, 1979). 
2.4.3 Spatial Span 
Spatial Span Forward and Backwards is a discriminator of visual-spatial processing and working 
memory. The examiner takes a standardised board with 10 cubes in set positions on the board and 
points to a predetermined series of cubes. The subject is required to repeat the series in the same 
order (forward span) or in reverse order (backwards span). The sequences gradually increase in length 
as the test proceeds, from a minimum of 2 cubes, to a maximum of 9 cubes. One point is scored for 
each correct series, resulting in a maximum score of 16 in both parts of the test. Both tests are 
validated discriminators of cognitive impairment but spatial span backwards is more sensitive 
(Wiechmann et al., 2011). Spatial Span forward mainly tests attention. Spatial Span backward tests 
working memory and executive function as information must be held in the memory and processed. 
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2.4.4 Digit Span 
Digit Span is similar to spatial span, but instead of a having to repeat a series of tapping cubes, the 
subject has to repeat a series of digits that are read to him. Again there is a forwards and a backwards 
component of the test and the series grows in length as the test proceeds. Digit Span forwards mainly 
tests auditory attention. Digit Span backwards mainly tests working memory and executive function. 
2.4.5 ACER 
This test (not listed in Fig 2.4) is an assessment of global cognitive function. It has been validated as a 
discriminant of even mild cognitive dysfunction (Mioshi et al., 2006). It incorporates the Mini Mental 
State Examination (MMSE), the most widely used screening tool for a global assessment of cognitive 
function (Folstein et al., 1983), but also encompasses cognitive domains not assessed in the MMSE 
including attention, orientation, memory, verbal fluency, language and visuospatial skills. 
The test comprises a series of questions and simple tasks such as memorising an address, obeying a 3 
stage command and drawing a clock face. ACE-R is available and has been validated in many languages 
(including English, Japanese, Cantonese, Italian and Slovak. It takes approximately 15 minutes to 
complete the test. There are 26 tasks in total with a maximum possible score of 100, with individual 
scores for each domain. There are age and education dependent norms for the total score as well as 
for the individual domains. A cut-off score of 88 is 94% sensitive and 89% specific for the diagnosis of 
dementia. A cut-off of 82 is 84% sensitive and 100% specific. 
 
2.5  ASSESSMENT OF BRAIN STRUCTRE 
In this Thesis Magnetic resonance imaging has been used to assess the impact of OSA on brain 
structure. The principle of MRI is outlined below with a brief description of the methods of image 
analysis. The details of the scanners and the scanning protocols used in each study will be given in 
Chapters 3, 4 and 5. 
 
2.5.1. Magnetic resonance imaging 
MRI utilises the magnetic properties of hydrogen ions within the body to produce detailed images. 
Each hydrogen ion consists of a single proton. This proton spins on its axis. In normal circumstances 
42 
 
the direction of spin is random, but, because a proton has positive electrical charge, when a strong 
magnetic field is applied to the body, the protons’ spins align.  
A radiofrequency pulse produced at the same frequency as the protons are spinning, will cause the 
protons to absorb the energy from the pulse and change the direction of their spins. When the 
radiofrequency is removed, the protons will release these quanta of energy and return to their relaxed 
state. These quanta are detected by the MR receiver and allow the position of hydrogen ions within 
the body to be determined.   
 
In order to produce contrast between different tissue types, MRI relies on the different speeds at 
which different tissues lose their energy after the RF pulse has been turned off. This occurs through 
two processes: T1 recovery refers to transfer of energy from nuclei to the surrounding environment. 
T2 recovery refers to the loss of energy through inhomogeneities in the intrinsic magnetic field. This 
recovery occurs at different rates in different tissues. Scans can be either T1 or T2 weighted, referring 
to the process by which contrast is achieved.  
2.5.2. Image analysis 
Cortical reconstruction and volumetric segmentation was performed with the Freesurfer image 
analysis suite, which is documented and freely available for download online 
(http://surfer.nmr.mgh.harvard.edu/). 
The description given here is written by the software’s authors and is how they request that the 
analysis is described. 
“The technical details of these procedures are described in prior publications (Dale et al., 
1999; Dale and Sereno, 1993; Fischl and Dale, 2000; Fischl et al., 2001; Fischl et al., 2002; 
Fischl et al., 2004a; Fischl et al., 1999a; Fischl et al., 1999b; Fischl et al., 2004b; Han et al., 
2006; Jovicich et al., 2006; Segonne et al., 2004, Reuter et al. 2010, Reuter et al. 2012). Briefly, 
this processing includes motion correction and averaging (Reuter et al. 2010) of multiple 
volumetric T1 weighted images (when more than one is available), removal of non-brain 
tissue using a hybrid watershed/surface deformation procedure (Segonne et al., 2004), 
automated Talairach transformation, segmentation of the subcortical white matter and deep 
gray matter volumetric structures (including hippocampus, amygdala, caudate, putamen, 
ventricles) (Fischl et al., 2002; Fischl et al., 2004a) intensity normalization (Sled et al., 1998), 
tessellation of the gray matter white matter boundary, automated topology correction (Fischl 
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et al., 2001; Segonne et al., 2007), and surface deformation following intensity gradients to 
optimally place the gray/white and gray/cerebrospinal fluid borders at the location where the 
greatest shift in intensity defines the transition to the other tissue class (Dale et al., 1999; 
Dale and Sereno, 1993; Fischl and Dale, 2000). Once the cortical models are complete, a 
number of deformable procedures can be performed for further data processing and analysis 
including surface inflation (Fischl et al., 1999a), registration to a spherical atlas which is based 
on individual cortical folding patterns to match cortical geometry across subjects (Fischl et 
al., 1999b), parcellation of the cerebral cortex into units with respect to gyral and sulcal 
structure (Desikan et al., 2006; Fischl et al., 2004b), and creation of a variety of surface based 
data including maps of curvature and sulcal depth. This method uses both intensity and 
continuity information from the entire three dimensional MR volume in segmentation and 
deformation procedures to produce representations of cortical thickness, calculated as the 
closest distance from the gray/white boundary to the gray/CSF boundary at each vertex on 
the tessellated surface (Fischl and Dale, 2000). The maps are created using spatial intensity 
gradients across tissue classes and are therefore not simply reliant on absolute signal 
intensity. The maps produced are not restricted to the voxel resolution of the original data 
thus are capable of detecting submillimeter differences between groups. Procedures for the 
measurement of cortical thickness have been validated against histological analysis (Rosas et 
al., 2002) and manual measurements (Kuperberg et al., 2003; Salat et al., 2004). Freesurfer 
morphometric procedures have been demonstrated to show good test-retest reliability across 
scanner manufacturers and across field strengths (Han et al., 2006; Reuter et al., 2012)”. 
To extract reliable volume and thickness estimates, images where automatically processed with the 
longitudinal stream (Reuter et al., 2012) in FreeSurfer. Specifically an unbiased within-subject 
template space and image is created using robust, inverse consistent registration (Reuter et al., 2010). 
Several processing steps, such as skull stripping, Talairach transforms, atlas registration as well as 
spherical surface maps and parcellations are then initialized with common information from the 
within-subject template, significantly increasing reliability and statistical power (Reuter et al., 2012). 
One of the advantages of using FreeSurfer is that the longitudinal stream (LS) has specifically been 
designed to analyse longitudinal data, unlike other analysis techniques, such as voxel based 
morphometry and deformation based morphometry (DBM), which were designed specifically to 
analyse cross sectional data. DBM has been shown to overestimate the rate of hippocampal 
degeneration in Alzheimer’s disease (AD) (Yushkevich et al., 2010).  Thompson and Holland recognised 
that the majority of brain degeneration in AD demonstrated using tensor based morphometry 
occurred in the first six months. By using the same techniques, they were able to demonstrate similar 
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changes using serial images acquired from healthy controls (Thompson & Holland, 2011). This 
reduction in test-retest reliability is likely to be due to several factors, including motion artefact, 
change of head and jaw position and variability in image processing .(Reuter & Fishel 2011). 
The longitudinal stream has been validated, and found to reduce within-subject variability compared 
to the cross-sectional (CS) analysis techniques, when used to analyse two sets of MR images obtained 
from the same healthy subjects on the same day, as well as four sets of images of healthy controls 
obtained over a period of 14 days (Reuter et al., 2012). MR images were obtained twice in the same 
session, using the same protocol, from 115 healthy subjects and analysed using both LS and CS. There 
was significantly less volume change in all brain regions, including thalamus and hippocampus when 
using LS [mean dice coefficient (SD): LS, 0.942 (0.030) vs CS, 0.859 (0.058); p<0.001] (Reuter et al., 
2012). LS was also  shown to have better test retest agreement in all brain structures than CS when 
analysing images obtained from healthy subjects multiple times over several weeks at 8 different sites 
[e.g. hippocampus dice coefficient (SD): LS, 0.92 (0.02) vs CS, 0.87 (0.02); p<0.001, thalamus dice 
coefficient (SD): LS, 0.94 (0.03) vs CS, 0.89 (0.04); p<0.001]. This study also showed that LS gives higher 
spatial consistency than CS across multiple sites (p<0.01) (Jovicich et al., 2013) i 
FreeSurfer analysis can detect the increased cortical volume loss over 2.5 years seen in patients with 
early AD relative to age matched healthy controls [mean % volume loss (SD): AD, 3.45 (1.51) vs controls 
0.64 (1.06); p<0.05] (Adriaanse et al., 2014). Furthermore, this volume loss was not seen in the motor 
or sensory cortices . This suggests that the increased volume loss seen in AD patients is not a result of 
systematic measuring errors and is consistent with evidence from other imaging modalities that these 
areas are relatively preserved in early AD (Svarer et al., 2005). LS analysis has been shown to be more 
sensitive than CS to the different  brain volume loss between healthy controls and patients with AD 
and also between healthy controls and patients with Parkinson’s disease (Reuter et al., 2012). 
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Chapter 3 
THE ASSOCIATION BETWEEN OF OSA AND 
HIPPOCAMPAL HYPERTROPHY 
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3.1 SUMMARY 
The impact of OSA on neural structure and function is unclear. Preclinical studies suggest that 
intermittent hypoxia (IH) and sleep fragmentation, both common in OSA, can affect the brain by 
disrupting hippocampal neurogenesis. Previous studies from the Brompton Sleep Group have shown 
grey matter loss in patients with OSA, compared to healthy controls. However, in animal models the 
notion of a biphasic response to chronic IH has been proposed. Prior to the study presented in this 
thesis there was little evidence for increased ‘compensatory’ neurogenesis in humans with OSA.  
The objective of this study was to carry out a re-analysis of previously collected data to determine the 
effect of OSA on hippocampal, thalamic and cerebellar volumes: in prior studies these structures are 
most consistently shown to be affected. A cross-sectional case-control study was completed using 
structural MRI. 
MRI scans from thirty two patients with mixed severity OSA (mean [SD]: AHI, 42.3 [23.81] events/h; 3 
women; age 48.5 [12.51] years) and 33 non-apnoeic controls (AHI: 2.1 [1.61]) events/h; 5 women; age 
49.7 [11.30] years) were analysed to determine hippocampal, thalamic and cerebellar volumes. 
Inferential analysis showed that the hippocampi were bilaterally larger in the OSA group than in the 
healthy control group; on the non-dominant (right) side this reached significance (p=.029). No 
significant difference in cerebellar volume was noted between the OSA patients and healthy controls. 
Although a trend towards smaller thalami in the OSA group was also noted, with larger reductions on 
the non-dominant side, this did not reach significance (p=.09). Inter-regional correlation analysis 
suggested aberrant connectivity between hippocampal and thalamic structures and the cerebellum in 
the OSA group. 
The finding presented in this study suggests that hypertrophy of hippocampus can occur in young and 
middle-aged OSA patients with mixed disease severity. The possible role of hypoxia preconditioning 
in the neuropathology of OSA is discussed, and the clinical functional implications of these changes 
are investigated in Chapter 4. The effects of aging on neuroplasticity in older OSA patients are 
discussed in Chapter 5. 
Contributions: The study was designed by Rosenzweig, Morrell, Glasser and Kempton. The data were 
previously acquired by Morrell and Corfield. Analysis and interpretation of data were carried out by 
Glasser, Rosenzweig, Milosevic, Beniczky and Williams. Data have now been published in a manuscript 
with Rosenzweig, Glasser, Kempton, Crum, Beniczky, Williams and Morrell as authors. Statistical 
analysis was carried out by Milosevic and Beniczky. 
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3.2 INTRODUCTION 
OSA is a prevalent multisystem disease affecting up to 13% of the population (See Chapter 1, Section 
1.2.2). It is predicted that it will become an even greater health problem in the future because rates 
of two of its most important risk factors, obesity and older age, are increasing.(Durgan & Bryan, 2012; 
Li & Veasey, 2012). This means that it is important to understand the consequences of OSA, and to 
ensure that treatment strategies are optimal. 
OSA patients experience recurrent collapse of their upper airway that produces apnoeas and 
hypopnoeas, resulting in intermittent hypoxia (IH). Each event is terminated by an arousal from sleep, 
resulting in reoxygenation, and producing fragmented sleep patterns.(Gozal, 2013a; Rosenzweig et 
al., 2013b) It has been suggested that in older people the intermittent hypoxia and fragmented sleep 
may accelerate brain atrophy, cognitive decline, and may even increase the severity of 
dementia.(Fotuhi et al., 2009; Ayalon et al., 2010; Durgan & Bryan, 2012; Gozal, 2013a). The 
mechanism of this cognitive impairment may be mediated by the impact of the intermittent hypoxia 
and / or sleep fragmentation on neurogenesis and brain structure, particularly in the hippocampus 
(see Chapter 1, Section 1.4). However, a review of the changes in brain morphology associated with 
OSA shows that multiple regions are influenced, and that the overall picture is confusing (see Table 
3.1). 
The differences shown in Table 3.1 are likely to be caused by the use of different image analysis 
methods in the reported studies. Over the years the techniques for analysis of MRI scans have 
improved; in addition the statistical thresholds used in the analysis varied (Morrell & Glasser, 2011). 
Nevertheless, this explanation does not take into account the between-subject variability to a given 
hypoxic stimulus (Rosenzweig et al., 2013b, d) or the within-subject differences across multiple brain 
regions. Additionally, it does not account for any cardiovascular and cerebrovascular protection 
conferred by ischaemic preconditioning, resulting from the nocturnal cycles of hypoxia-reoxygenation 
(Lavie & Lavie, 2006; Rosenzweig et al., 2013b). The role of ischaemic preconditioning, which 
represents a generalized adaptation to ischaemia is described in detail in Chapter 1, Section 1.4.1. 
(Lavie & Lavie, 2006; Dirnagl et al., 2009) 
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Table 3.1: A review of studies that have used MRI (voxal based morphomatry) in OSA (Morrell & 
Glasser, 2011) 
 
3.2.1. Neurogenesis and the role of intermittent hypoxia in OSA 
New neurons are produced on a continuous basis in the healthy adult human brain, with neural 
stem/progenitor cells residing in two major neurogenic regions: the subventricular zone lining the 
lateral ventricles and the dentate gyrus (DG) of the hippocampal formation (Seki, 2011). Additional 
sites of neurogenesis, such as the temporal horn, thalamus, striatum, cerebellum and cortex have 
been reported in some animal models (Seki, 2011). Hypoxic/ischaemic insults in rodent models are 
powerful stimuli of adult neuronal cell production in both neurogenic areas and otherwise dormant 
regions such as the striatum and hippocampal pyramidal cell layer CA1 (Lichtenwalner & Parent, 2006) 
– Also see Fig 3.1 Top panel. 
In the classic study of (Gozal et al., 2001), chronic intermittent hypoxia in animal models of OSA was 
associated with impaired spatial learning that coincided with the increased structural change in the 
cortex and CA1 region of the hippocampus (Gozal et al., 2003b; Gozal et al., 2003c; Haddad & Yu, 
2009). Moreover, these researchers demonstrated increased cell proliferation in the dentate gyrus at 
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a later stage of this process, which was present in spite of the ongoing intermittent hypoxia. Therefore 
the biphasic, temporal change in dentate gyrus proliferation may account for the partial recovery of 
clinical function in the later stages of IH exposure (Gozal et al., 2003b). Several other preclinical studies 
have also reported a ‘protective’ response to moderate intermittent hypoxia(Jung et al., 2008; Haddad 
& Yu, 2009) suggesting that ischaemic preconditioning-like processes may occur. For example, in one 
rodent model, the intermittent hypoxia intervention after the ischaemic event led to increased 
expression of brain derived neurotrophic factor (BDNF), increased hippocampal neurogenesis and 
functional synaptogenesis, as well as in improvement in spatial learning and long-term memory 
impairment (Tsai et al., 2011; Tsai et al., 2013). In another study, intermittent hypoxia in adult rats 
was also shown to promote hippocampal neurogenesis, and to mimic antidepressant-like effects (Zhu 
et al., 2010). 
Despite the animal data suggesting the association between chronic intermittent hypoxia, ischaemic 
preconditioning and the subsequent adaptive increase in adult neurogenesis in several affected brain 
regions, this putative association has not so far been shown conclusively in clinical studies of brain 
changes in OSA (Table 3.1) (Macey et al., 2002; Morrell et al., 2003; Macey et al., 2008; Yaouhi et al., 
2009; Joo et al., 2010; Morrell et al., 2010; Torelli et al., 2011). To date, volumetric, predominantly 
voxel based morphology (VBM), studies of brain changes in OSA patients indicate a predominantly 
hypotrophic effect in a number of cortical regions and subcortical structures (Macey et al., 2002; 
Morrell et al., 2003; O'Donoghue et al., 2005; Macey et al., 2008; Yaouhi et al., 2009; Morrell et al., 
2010; Torelli et al., 2011). This includes the findings of studies carried out by my own group at the 
Brompton Hospital. However, there is high variability in results across clinical studies of OSA and the 
neuroimaging methods used in earlier studies might not be sufficiently sensitive to capture the subtle 
and spatially diffuse changes in regions such as the hippocampal formation. The connectivity between 
these regions is also important in describing the neurocircuitry of OSA neuropathology (Gozal, 2013b; 
Rosenzweig et al., 2013b).  
In order to address some of these issues, I decided to re-analysis the magnetic resonance imaging 
scans, previously obtained by my group, using a fully automated volumetric analysis method, 
FreeSurfer (FS). Specifically I wished to study the changes in several subcortical structures in OSA 
patients with different severity of disease, and age-matched healthy controls (Doring et al., 2011). The 
FS method is more fully described in Chapter 2, Section 2.3.6. It has also now been validated in a 
number of clinical studies where it was shown to be efficient in quantifying subcortical volumes in 
dementia (Pengas et al., 2009), epilepsy (McDonald et al., 2008), depressive disorders (Tae et al., 2008) 
and aging (Walhovd et al., 2005). The hypothesis investigated in the study presented in this thesis was 
50 
 
that volumes in the hippocampus, thalamus and cerebellum would differ across diagnostic groups. 
Analysis of the MR scans used in this study has been previously published as a sub-set of a wider study 
(Morrell et al., 2010); the hypothesis and techniques used in this chapter are different. 
 
3.3 METHODS 
Patients were recruited from Royal Brompton and Charing Cross Hospitals sleep clinics. Inclusion 
criteria were: AHI >15 events/h. Exclusion criteria were: a history of other respiratory disease, 
cerebrovascular disease or ischaemic heart disease, diabetes mellitus, a neurological or psychiatric 
disorder, alcohol or illicit drug abuse, or current intake of psychoactive medications. 
Healthy controls were recruited through a database of healthy volunteers. Exclusion were: a history 
of habitual snoring or any other sleep complaint. All control subjects were screened with 
polysomnography and questionnaires to exclude OSA (AHI <5 events/h).  
The study was approved by the ethics committee of the Royal Brompton Hospital (Ref: 01-160), and 
all patients and healthy volunteers gave informed written consent. 
 
3.3.1 Measurements and Analysis 
The protocol and measurements made during nocturnal sleep studies are described in Chapter 2, 
Section 2.2. Apnoeas were defined as >80% drop in airflow for 10s and hypopneas were defined as 
>50% reduction in airflow from baseline with a >4% dip in saturation, or an arousal from sleep.  
3.3.2 Magnetic resonance imaging and analysis  
The principle of MRI is described in Chapter 2, Section 2.5.1. In the study presented in this chapter all 
participants underwent MR imaging at the Charing Cross Hospital. T1-weighted MR images were 
acquired using a 1.5T scanner (Magnetom Vision, Siemens Healthcare, Camberley, Surrey, UK) and a 
3D MP-RAGE sequence (TI 300 ms, TE 4 ms, in-plane resolution 1.031.0 mm) with contiguous 2 mm 
coronal slices. 
The T1-weighted images were processed and volumetry performed using an automated method 
unbiased by non-linear registration, FS, as previously described in Chapter 2, Section 2.5.2. (Fischl et 
al., 2002; Walhovd et al., 2005; Tae et al., 2008; Cerasa et al., 2009; Pengas et al., 2009; Doring et al., 
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2011). In summary during this fully automated process removal of non-brain tissue, automated 
Talairach transformation, segmentation of the subcortical white matter (including segmentation of 
the corpus callosum to five parts) (Webb et al., 2012) and deep grey-matter volumetric structures, 
intensity normalization, and cortical reconstruction were performed. A neuroanatomical label to every 
voxel in the MR image volume was assigned and the Markov Random Field Theory was applied, where 
the probability of a label at a given voxel was computed not just in terms of the grey-scale intensities 
and prior probabilities at that voxel, but also as a function of the labels in a neighbourhood of the 
voxel in question. Given the a priori hypothesis regarding the differences in hippocampal volumes, this 
step was particularly pertinent as it enabled correct separation of the hippocampus and amygdala, 
which have similar grey-scale values (Doring et al., 2011). 
The analysis was performed for all scans on the same workstation using parallel running streams with 
no variability to the data processing conditions (Gronenschild et al., 2012). The segmented 3D images 
of structures of interest were inspected for gross errors through visualization with 3D slicer (Version 
3.2 1.0, NIH, USA) (IR), and the volume values were extracted by implemented Unix scripts by Dr 
Crumm and Dr Kempton. 
3.3.3 Statistical Testing 
The Kolmogorov-Smirnov test was used to test the normality of distributions. To analyse differences 
in variety of demographic parameters between controls and OSA patients, a student’s t-test was 
initially applied. All statistical analyses had a 2-tailed  level of <.05 for defining significance and were 
performed by a biostatistician on the statistical software “STATISTICA 10.0” 
(http://www.statsoft.com). 
The gender differences between the two groups were found to be non-significant (Pearson Chi-Square 
test, p=.479). The intracranial volume (ICV) calculated by the FS did not differ significantly between 
groups (Appendix 3.1) and a one-way analysis of covariance (ANCOVA) was conducted (using age as a 
covariant) on the ICV controlled data to assess between-group differences. Finally, the presumed 
inter-regional connectivity between the hippocampi and thalami and cerebellar cortices was explored 
using Pearson correlations; controlled for ICV and age.(Plessen et al., 2006)  
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3.4 RESULTS 
Sixty five participants were studied with MR neuroimaging. Demographic data is given in Table 3.2.  
Table 3.2. Demographic Information 
 OSA 
n= 32; mean [SD] 
Control 
n= 33; mean [SD] 
Age [years] 48.50 [12.51] 49.73 [11.30] 
BMI [kg/m2]* 31.48 [4.34] 24.76 [3.66] 
AHI [events/h]* 42.3 [23.81] 2.1 [1.61] 
ODI [events/h]* 31.4[19.43] 1.2 [1.33] 
ESS* 13.2 [4.64] 4.7 [3.69] 
Right-handedness [%] 100 100 
 
*Significant difference between OSA patients and healthy controls (P<.001). There was no significant 
difference in the age between the two groups (P=.68). Normality was checked using Kolmogorov-
Smirnov test. The plots appeared approximately normally distributed so independent sample t-test 
statistics were used to compare patients and controls. Abbreviations: AHI, apnoea/hypopnoea index; 
BMI, body mass index; ESS, Epworth sleepiness scale; n, number; ODI, oxygen desaturation index; 
OSA, obstructive sleep apnoea; SD, standard deviation.  
 
The a priori hypothesis investigation concentrated on analysis of group differences for three 
neuroanatomical structures previously shown to be affected in OSA; the hippocampus, thalamus and 
cerebellum. The hippocampus was found to be larger bilaterally in the OSA group and hypertrophy in 
the right hippocampus was statistically significant (absolute mean values: OSA, 4336.5mm3 vs control, 
4090.6mm3; F (1,62)=5.02, P=.029). A statistically non-significant trend for smaller thalami in the OSA 
group was also noted, more so on the right (absolute mean values: OSA, 6718.9mm3 vs control, 
7056.4mm3; F (1,62)= 2.9, P=.092). No statistically significant differences were noted between 
cerebellar cortical and white matter volumes of the two studied groups (Table 3.3). 
Amongst the values for several other subcortical structures automatically calculated by FS, only two 
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more group differences in volume reached statistical significance; those of choroid plexus and the 
middle anterior portion of the corpus callosum. Both left (F (1,62)=4.39, P=.040) and right choroid 
plexus (F (1,62)=6.13, P=.016) (Table 3.3) were found to be hypertrophic in the OSA group. Conversely, 
the volume of the mid-anterior portion of the corpus callosum was significantly decreased in OSA 
patients (F (1,62)=4.26, P=.043). The hypertrophy of the right choroid plexus along with the 
hypertrophy of the right hippocampus in the OSA group was found to be statistically significant even 
when controlled for age (ICV controlled t-test; P<.05; Table 3.3). 
The results for the remaining subcortical structures by FS are summarised in Appendix 3.1. 
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Table 3.3. Subcortical Volumes as determined by analysis of brain MRI using FreeSurfer.  
Region  
Study 
Group 
n Mean [SD] mm3 
ANCOVAa P 
values 
t – testa P 
values 
Right 
Hippocampus 
Control  33 4090.58 [663.41] .029* .025* 
OSA 32 4336.47 [461.99]   
Left 
Hippocampus 
Control  33 4321.61 [483.03] .096 .084 
OSA 32 4453.81 [477.37]   
Right Thalamus  
Control  33 7056.39 [1037.81] .092 .212 
OSA 32 6718.88 [827.24]   
Left Thalamus  
Control  33 7190.27 [1042.69] .327 .547 
OSA 32 6965.72 [960.79]   
Right 
Cerebellum 
(Cortex) 
Control  33 54018.21 [5284.82] .461 .533 
OSA 32 52464.13 [4974.43]   
Left Cerebellum 
(Cortex) 
Control  33 52611.33 [5081.25] .401 .486 
OSA 32 51001.41 [5119.22]   
Right 
Cerebellum 
(White Matter) 
Control  33 15275.03 [2460.36] .399 .442 
OSA 32 14658.78 [1776.50]   
Left Cerebellum 
(White Matter) 
Control  33 15059.58 [2397.52] .849 .929 
OSA 32 14772.03 [1985.43]   
Right Choroid 
Plexus 
Control  33 1982.91 [446.91] .016* .035* 
OSA 32 2172.81 [476.45]   
Left Choroid 
Plexus 
Control  33 1733.67 [373.39] .040* .087 
OSA 32 1839.22 [371.26]   
Corpus Callosum 
(Middle Anterior 
Portion) 
Control  33 459.55 [139.62] .043* .078 
OSA 32 406.53 [72.13]   
In the table, for each neuroanatomical structure statistical analysis of group differences for ICV 
controlled volumes was performed; t-test and ANCOVA test (covariate with age),were done. 
aBonferroni corrected P values. *Significant difference between OSA patients and healthy controls 
(p<.05).  Abbreviations: ANCOVA, Analysis of covariance; ICV, intracranial volume; OSA, obstructive 
sleep apnoea; SD, standard deviation. 
 
Post hoc interregional volumes correlation analysis revealed an increased number of significant 
correlations between the cerebellar cortex and hippocampal and thalamic structures in the OSA group 
when compared to controls (Fig 3.1 bottom panel). On the non-dominant side, in the OSA group 
significant correlation was found between the right hippocampus and thalamus with the ipsilateral 
(hippocampus, r=.363; P=.041; thalamus, r=.407; P=.021) and the contralateral cerebellar cortex 
(hippocampus, r=.379; P=.032; thalamus, r=.455; P=.009). 
In the control group, the only significant correlation was found between right thalamus and the 
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contralateral cerebellar cortex (r=.349; P=.047). On the dominant side, in the OSA group, there was a 
significant positive correlation between left thalamus with both ipsilateral (r=.383; P=.030) and 
contralateral (r=.381; P=.031) cerebellar cortex. Only ipsilateral correlation was found significant for 
left hippocampus (r=.357; P=.045). Conversely, control subjects had no significant correlations. 
 
 
 
Figure 3.1: Dentate gyrus (DG) and CA1 (arrows) support neurogenesis in animal models of 
ischemia/OSA (Top left panel). Human hippocampal subfields are shown (coronal/sagittal planes), 
adapted from69 (Top right panel) Potential aberrant/additional connectivity between cerebellar 
cortices (arrows) and thalamus and hippocampus in OSA patients (Bottom panel).  
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3.5 DISCUSSION 
The main finding of this study was the coexistence of both hyper- and hypotrophic changes in the OSA 
group compared to healthy controls. To my knowledge these data provide some of the first 
experimental evidence that patients with OSA are exposed not only to noxious factors that cause brain 
injury, but also to mechanisms that act to repair brain tissue. This may be mediated by ischaemic 
preconditioning and enhanced neurogenesis. (Ferriero, 2005; Dirnagl et al., 2009; Seki, 2011) 
3.5.1 Hypertrophic changes and relation to previous studies 
The role for the altered neurogenesis and possible conditioning effect of OSA in the OSA patients was 
suggested by the significant increase of hippocampal volumes, which were up to 6% greater than in 
the control group. Additionally, the hypertrophy of the choroid plexus, an important source of adult 
neurogenic factors and signalling molecules for the migration of cells in the subventricular zone (Seki, 
2011), was also noted. These findings are compatible with reported hypertrophic change of these 
structures under ischaemic conditions (Comi, 2003).  
Previous clinical studies of the neural changes in OSA, including those from the Royal Brompton Group, 
have predominantly reported hypotrophic changes in OSA patients (see Table 3.1). Although the 
cross-sectional design of this study only permits associations to be described, and does not provide 
evidence of cause and effect, it is possible that both hyper- and hypotrophic changes could occur in 
OSA patients, as there are a range of plausible physiological explanations: Firstly, I studied patients 
with mixed disease severity and hence they potentially differed from other investigated cohorts that 
incorporated patients at the more severe end of the OSA spectrum. Indeed, the duration of the 
exposure to IH and the intensity of the bouts of hypoxia are important determinants of whether IH is 
protective or harmful (Jung et al., 2008; Haddad & Yu, 2009; Aviles-Reyes et al., 2010). Secondly, the 
patients were relatively young, mostly in their forties with no obvious major co-morbidities, and it is 
possible that the onset of OSA was relatively recent. The age-dependent decline in adult neurogenesis 
is an accepted phenomenon, although it appears to be mediated more by the age-related alterations 
in the cellular environment than impaired responsiveness of progenitor cells to neurogenic stimuli 
(Lichtenwalner & Parent, 2006). 
3.5.2 Automated FS analysis  
Unlike the earlier studies that utilized the optimized VBM method, this study used the fully automated 
FS analysis that has been proven particularly effective for analysis of subcortical structures (Fischl et 
al., 2002; Cerasa et al., 2009; Doring et al., 2011). Conversely, the whole-brain VBM method is 
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generally regarded as less sensitive than the other methods when it comes to detecting abnormalities 
in small subcortical structures (Cerasa et al., 2009). 
In a recent magnetic resonance spectroscopy study of OSA patients, decreased frontal lobe neuronal 
viability and integrity was shown, as was decreased hippocampal membrane turnover. However, 
when the structural MRI images were analysed using the VBM method no lesions in those regions 
were shown in the same patients (O'Donoghue et al., 2012). It should be noted that in animal studies, 
subregions of the hippocampus were shown to be differentially sensitive to chronic IH (Gozal et al., 
2003c; Aviles-Reyes et al., 2010; Papadakis et al., 2013). For example CA1 was particularly IH-sensitive 
and prone to increased levels of change in structure whilst CA3 and DG were significantly less so 
(Papadakis et al., 2013). DG was additionally able to undergo compensatory neurogenesis (Gozal et 
al., 2003b). Further enhancements of cognitive vulnerability to IH exposures occurred in CA1 in rats 
fed on an obesity-inducing diet (Goldbart et al., 2006). It is, hence, possible that depending on the 
balance of these changes and their overall offset, the whole volume of the hippocampus might be 
ultimately noted as either hyper- or hypotrophic; whereas in the current study I have been able to 
segment these effects, which represents a step forward and differs from previous papers from the 
Brompton group. Finally, volume increase in the hippocampus could represent an epiphenomenal, or 
downstream, effect of the connectivity with other brain regions, which include prefrontal cortex, 
amygdala and thalamus.  
3.5.3 Hypotrophic changes 
In the current study, hypotrophic changes were noted in OSA patients in the mid-anterior portion of 
the corpus callosum and the thalami. A trend towards smaller thalamic volumes in OSA group in 
comparison to controls was observed, but it did not reach statistical significance. This is in accordance 
with previous clinical studies and possibly supports the hypothesis that a disturbed thalamocortical 
oscillator underlies some of the neurocognitive deficits seen in OSA (Schonwald et al., 2012; 
Rosenzweig et al., 2013b). One of the major sources of thalamic afferents to the hippocampus (e.g. 
CA1 and subiculum) is the nucleus reuniens, the largest of the midline nuclei of the thalamus, the 
region known to be strongly activated by chronic IH (Sica et al., 2000; McKenna & Vertes, 2004). 
Nucleus reuniens has been implicated in associative learning and object recognition and it is proposed 
to gate information flow between the hippocampus and the medial prefrontal cortex (Aggleton et al., 
2010; Eleore et al., 2011). Similarly, the noted volume reduction of the mid-anterior portion of the 
corpus callosum in OSA patients in the current study is in agreement with previous diffusion 
tractography (DTI) studies of white matter tract changes; it likely represents the effects of IH on the 
later myelinating part of this tract (Kumar et al., 2012; Rosenzweig et al., 2012). 
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3.5.4 Correlations with cerebellar cortex volumes 
The Royal Brompton group has previously shown hypotrophic changes in the cerebellar cortices of 
OSA patients (Morrell et al., 2010). It is possible that the functional deficits noted in OSA, could be 
seen as the by-product of being at the milder end of a spectrum of cerebellar cognitive affective 
syndrome (Schmahmann & Sherman, 1998; Rosenzweig et al., 2013b). In the study presented in this 
chapter, no significant difference in cerebellar volumes was recorded, although aberrant connectivity 
with hippocampal and thalamic structures was suggested by the interregional volume correlations 
analysis (Figure 3.1 – bottom panel). This suggestion is in broad agreement with previous VBM and 
DTI studies (Kumar et al., 2012; Macey, 2012). Whilst these volumetric correlations can be only very 
tentatively taken to suggest a true aberrant connectivity (Plessen et al., 2006). in the OSA group, they 
nonetheless circumstantially intimate that ‘compensatory’ entraining of the cerebellum by a 
hypertrophic hippocampus may occur. 
3.5.5 Limitations 
Limitations of this study include the moderate sample size and cross-sectional design, which can 
suggest only an association, rather than a causal relationship between the neural changes noted in 
OSA patients and the mechanisms of intermittent hypoxia and sleepiness. 
This study did not incorporate neuropsychological testing and the lack of the related correlational data 
with the noted volumetric changes means that no conjecture about the compensatory role of the 
prominent enlargement of hippocampi can be made. Furthermore, correlations between regional 
volumes were exploratory and hypothesis-generating and therefore should be interpreted with 
caution. They will need to be confirmed in future studies. 
It should be noted that the ultra-structural determinants of group differences in morphology of the 
hippocampus and thalamus are unknown. Addressing these limitations would require detailed post-
mortem and other in vivo (adult neurogenesis) imaging methods in order to determine those ultra-
structural underpinnings. 
Finally, the strict exclusion criteria used in this study does not allow any judgments to be made 
regarding interactions between OSA and its comorbidities such as hypertension and diabetes, both 
strongly associated with OSA and known to also cause brain injury (Devisser et al., 2011; Li & Veasey, 
2012; Gozal, 2013a). 
3.5.6. Conclusions  
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In summary, these findings demonstrate for the first time to my knowledge hypertrophy of the 
hippocampus in OSA patients with mixed disease severity. It is proposed that these enlargements 
represent the end product of neuroglial ischaemic preconditioning (Ferriero, 2005; Lichtenwalner & 
Parent, 2006; Nanduri et al., 2008; Dirnagl et al., 2009; Aviles-Reyes et al., 2010). This interpretation 
is consistent with extensive preclinical evidence that increased hippocampal neurogenesis occurs in 
response to IH, which consequently  leads to increases in hippocampal volume and thickness (Gozal 
et al., 2003b; Lichtenwalner & Parent, 2006; Zhu et al., 2010; Bonnici et al., 2012). Aberrant 
connectivity between limbic regions, the prefrontal cortex and the cerebellum was also inferred by 
the study. 
It has been previously suggested that increasing age and OSA work additively (or even 
synchronistically) to overwhelm the brain’s capacity to respond to cognitive challenges with 
compensatory recruitment, and to maintain performance (Ayalon et al., 2010; Sforza & Roche, 2012; 
Gozal, 2013a). It would, therefore, be important to recognise which compensatory mechanisms 
evoked by OSA are functionally viable and which may be further detrimental, especially in older 
people. I will begin to explore these issues in an MRI study carried out in older people, presented in 
Chapter 5.   
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Appendix 3.1: Table Shows the Percentage Ratios of Subcortical Volumes to 
the ICV as determined by the FreeSurfer 
Structures  N Mean Std. 
Deviation 
Student t-testa 
P values 
ANCOVAa P 
values 
L-Cerebellum-White-Matter OSA 32 0.972 0.130 0.929 0.849 
 Control 33 0.975 0.153   
L-Cerebellum-Cortex OSA 32 3.353 0.289 0.486 0.401 
 Control 33 3.408 0.339   
L-Thalamus-Proper OSA 32 0.457 0.046 0.547 0.327 
 Control 33 0.464 0.055   
L-Caudate OSA 32 0.229 0.028 0.214 0.235 
 Control 33 0.221 0.027   
L-Putamen OSA 32 0.373 0.045 0.276 0.316 
 Control 33 0.361 0.048   
L-Pallidum OSA 32 0.111 0.012 0.827 0.732 
 Control 33 0.112 0.014   
L-Hippocampus OSA 32 0.293 0.032 0.084 0.096 
 Control 33 0.280 0.030   
L-Amygdala OSA 32 0.108 0.012 0.289 0.327 
 Control 33 0.104 0.016   
L-choroid-plexus OSA 32 0.120 0.020 0.087 0.040 
 Control 33 0.112 0.020   
R-Cerebellum-White-Matter OSA 32 0.964 0.104 0.442 0.399 
 Control 33 0.990 0.163   
R-Cerebellum-Cortex OSA 32 3.450 0.281 0.533 0.461 
 Control 33 3.498 0.340   
R-Thalamus-Proper OSA 32 0.441 0.038 0.212 0.092 
 Control 33 0.456 0.056   
R-Caudate OSA 32 0.230 0.026 0.609 0.661 
 Control 33 0.227 0.024   
R-Putamen OSA 32 0.353 0.042 0.263 0.302 
 Control 33 0.340 0.047   
R-Pallidum OSA 32 0.104 0.012 0.554 0.619 
 Control 33 0.101 0.016   
R-Hippocampus OSA 32 0.285 0.030 0.025 0.029 
 Control 33 0.265 0.042   
R-Amygdala OSA 32 0.105 0.013 0.114 0.129 
 Control 33 0.099 0.015   
R-choroid-plexus OSA 32 0.142 0.026 0.035 0.016 
 Control 33 0.128 0.026   
CC_Posterior OSA 32 0.060 0.007 0.514 0.522 
 Control 33 0.058 0.010   
CC_Mid_Posterior OSA 32 0.027 0.005 0.330 0.381 
 Control 33 0.026 0.006   
CC_Central OSA 32 0.027 0.007 0.505 0.433 
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 Control 33 0.028 0.007   
CC_Mid_Anterior OSA 32 0.027 0.004 0.078 0.043 
 Control 33 0.030 0.009   
CC_Anterior OSA 32 0.057 0.007 0.954 0.969 
 Control 33 0.057 0.011   
SubCortGrayVol OSA 32 11.917 0.820 0.843 0.704 
 Control 33 11.962 0.992   
 
In the table, for each neuroanatomical structure statistical analysis of group differences for ICV controlled 
volumes was performed; t-test and ANCOVA test (covariate with age), were performed. aBonferroni 
corrected P values. *Significant difference between OSA patients and healthy controls (p<.05). 
Abbreviations: ANCOVA, Analysis of covariance; CC, corpus callosum; ICV, intracranial volume; OSA, 
obstructive sleep apnoea; SD, standard deviation. L: Left, R: Right 
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Chapter 4 
CHANGES IN NEUROCOGNITIVE FUNCTION AND 
BRAIN MORPHOLOGY IN OSA PATIENTS TREATED 
WITH CPAP4.1 SUMMARY 
Treatment with CPAP offers some protection from the effects of OSA, although it is still unclear which 
populations should be targeted, for how long, and what the effects of treatment are on different organ 
systems. The focus of this Thesis is specifically neurocognitive and brain function.The objective of this 
study was to investigate whether cognitive improvements could be achieved as early as one month 
into CPAP treatment in patients with OSA. 
Fifty-five patients (mean (SD) age: 47·6 (11·1) years) with newly diagnosed moderate-severe OSA (ODI: 
36·6 (25·2) events/hour; ESS: 12·8 (4·9) units) and 35 matched healthy volunteers were studied. All 
participants underwent neurocognitive testing, neuroimaging and polysomnography. Patients were 
randomised into parallel groups: CPAP with BSC, or BSC alone for one month, after which they were 
re-tested. I found that one month of CPAP with BSC resulted in a hypertrophic trend in the right 
thalamus [mean difference (%): 4·04, 95%CI 1·47 to 6·61], which was absent in the BSC group [-2·29, 
95%CI -4·34 to -0·24]. Significant improvement was also recorded in ESS, in the CPAP plus BSC group, 
following treatment [mean difference (%): -27·97, 95%CI -36·75 to -19·19 vs 2.46 95%CI -5·23 to 10·15; 
P=0·012], correlated to neuroplastic changes in brainstem (r=-0·37; P=0·05), and improvements in 
delayed logical memory scores [57·20, 95%CI 42·94 to 71·46 vs 23·41 95%CI 17·17 to 29·65; P=0·037].  
The finding presented in this study suggest that one month of CPAP treatment can lead to adaptive 
alterations in the neurocognitive architecture that underlies the reduced sleepiness, and improved 
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verbal episodic memory in patients with OSA. Therefore even short treatment periods can lead to 
partial neural recovery and this information can be used to encourage patients to use CPAP therapy. 
Contributions: The study was designed by myself, Prof Morrell and Dr Rosenzweig. I carried out all the 
data collection and analysis except the operation of the MRI scanner, and the manipulation of the 
FreeSurfer MRI. Statistical analysis was carried out with the help of Drs Rosenzweig and Milosevic. 
Interpretation of data was carried out by Glasser, Rosenzweig and Morrell. 
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4.2 INTRODUCTION 
OSA is a chronic sleep disorder that arises from recurrent partial or complete pharyngeal obstruction 
during sleep (see Chapter 1, Section 1.2.1). The close association of OSA with early onset of cognitive 
decline, by as much as a decade, has been reviewed in Chapter 1, whilst a growing body of clinical and 
animal work advocates that OSA should be recognized as one of the rare modifiable risks for 
accelerated cognitive decline is discussed in Chapter 1, and illustrated by the findings of Chapter 3. In 
addition, treatment with CPAP, the main treatment for OSA, has also been shown to halt the onset, 
decelerate the progression, or offer a better prognosis in patients with co-morbid dementia, epilepsy 
and stroke (Campos-Rodriguez et al., 2014; Pornsriniyom et al., 2014; Yaffe et al., 2014; McMillan et 
al., 2015; Osorio et al., 2015). 
The additive impact of progressive changes in sleep quality and structure, changes in cerebral blood 
flow, neurovascular and neurotransmitters, plus the cellular redox status are all likely to contribute to 
the cognitive deficits reported in up to one in  four newly diagnosed OSA patients (Lavie, 2015; 
Rosenzweig et al., 2015), Despite concerted efforts, OSA remains widely underdiagnosed in the 
general population, with its prevalence predicted to increase sharply over the coming years due to 
ageing and the epidemic of obesity (Heinzer et al., 2015; Lévy et al., 2015). The important questions 
of what, who and when to treat, are far from clear (Djonlagic et al., 2015; Rosenzweig et al., 2015). 
Persistent deficits, even after prolonged treatment with CPAP in some patients, suggest that early 
detection of the central nervous system (CNS) sequelae in OSA could be crucial (Castronovo et al., 
2014; Rosenzweig et al., 2015). 
In a recent study of patients with OSA, augmentation of subjective experience, attention and vigilance 
has been demonstrated after only one night of CPAP (Djonlagic et al., 2015). However, no appreciable 
impact on procedural memory consolidation was noted, suggesting differential impact on brain 
structures underlying these processes (Djonlagic et al., 2015). On the other hand, in a seminal study, 
three months of CPAP treatment led to a significant recovery of cognitive and morphometric deficits 
(Canessa et al., 2011). Taken together, empirical clinical experience and early research findings suggest 
that subjective memory improvements are reported as early as one month following the 
commencement of CPAP treatment (McMillan et al., 2015). 
In the present study, I aimed to investigate the timeframe over which CPAP treatment could produce 
changes in neurocognitive function and brain morphology. I tested the hypothesis that one month of 
CPAP treatment would lead to cognitive improvements, and that any changes would be associated 
with neuroplastic changes in patients with OSA.  
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4.3 METHODS 
4.3.1 Participants and Design 
Patients with newly diagnosed OSA (18-65 years old) were recruited from Royal Brompton and 
Harefield Hospitals sleep clinics. Inclusion criterion was an AHI >10 events/h. Exclusion criteria were a 
history of respiratory, cerebrovascular and/or ischaemic heart disease, diabetes mellitus, 
neuropsychiatric or neurological disorder, alcohol or drug abuse, or psychoactive medications.  
The same exclusion criteria were used for healthy controls (age- and education-matched) recruited 
from a database of healthy volunteers. Those with a history of sleep problems on questionnaires, or 
evidence of OSA on pulse-oximetry (ODI >5 events/h) were excluded.  
The study was approved by the UK central research ethics committee (10/H0706/51). All patients gave 
written informed consent.  
4.3.2 Measurements and Analysis 
All enrolled patients were randomly allocated [stratified by age, OSA severity (ODI & AHI) and years of 
education], by an independent study coordinator, to receive CPAP with BSC, or BSC alone, for one 
month and then re-assessed (Fig 4.1). 
CPAP treatment was initiated using standard clinical practice at each centre (ResMed S9; with 
humidification as required). BSC consisted of advice on minimising daytime sleepiness through sleep 
hygiene, naps, caffeine, exercise and weight loss as appropriate to each patient. Both groups were 
provided with BSC and asked to continue with their usual medical care during the trial.  
Structured assessments were performed at baseline (patients and controls) and at follow-up after one 
month (patients only). In addition, all patients received a telephone call at 1 week to record symptoms, 
side-effects, and to optimise CPAP adherence. All OSA patients completed an inpatient 
polysomnography (SOMNOscreen PSG, S-Med, UK – see Chapter 2, Section 2.2.3 for full details) prior 
to CPAP initiation. Domiciliary overnight pulse-oximetry (Konica-Minolta Inc,) was performed at one 
month. Treatment compliance was measured objectively by download of the CPAP smart card at the 
one-month visit. 
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Figure 4.1: CONSORT diagram 
 
Cognitive Tests Battery: A full description of the cognitive tests used in this chapter is given in Chapter 
2, Section 2.4. In brief, the cognitive function of all participants was assessed using a battery of tests 
comprising the Addenbrooke’s Cognitive Examination-Revised (ACE-R) (Graham et al., 2004; Mioshi et 
al., 2006), Trail Making Test A and B (Reitan, 1979) (TMA, TMB), Logical Memory (LM) Test: immediate 
and delayed LM with alternate stories used at baseline and follow up, subtests from the Wechsler 
Memory Scales (D, 1987), Digit Span Test: forward (DSF) and backward (DSB) (D, 1987), Spatial Span 
subtest  forward (SSF) and backward (SSB) (the visual-spatial version of Digit Span) (Wechsler, 1997). 
The tests used were chosen to target cognitive domains that have been previously shown to be 
affected by OSA from results of the Brompton Sleep group and other (Twigg et al., 2010; Rosenzweig 
et al., 2015). 
Magnetic Resonance Imaging: All participants underwent MR imaging at the Royal Brompton 
Hospital, and T1-weighted MR-images were acquired using a 1.5T scanner (Magnetom Vision, Siemens 
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Healthcare, Camberley, Surrey, UK) and a 3D MP-RAGE sequence (TI 300ms, TE 4ms, in-plane 
resolution 1·0x1·0mm) with contiguous 2mm coronal slices. The T1-weighted images were processed, 
and volumetry was performed using the automated method FreeSurfer, as previously described in 
Chapter 2, Section 2.5.2. 
4.3.3. Statistical Analyses 
The Kolmogorov-Smirnov test was used to test the normality of distributions. To analyse differences 
in a variety of demographic parameters between healthy controls and OSA patients, Student’s t-test 
was applied (Table 4.1). All statistical analyses had a 2-tailed α level of <0.05 for defining significance 
and were performed with the help of a biostatistician on the statistical software “STATISTICA 10·0” 
(http://www.statsoft.com). 
Investigation of a priori hypotheses was focused on group differences for several neuroanatomical 
structures that had been previously highlighted by my data (see Chapter 3) and that of other groups, 
to present network hubs of OSA-affected neurocircuitry: the hippocampus, amygdala, basal ganglia, 
thalamus, brainstem, corpus callosum (and its subdivisions) and cerebellum.(Gozal, 2013a; 
Rosenzweig et al., 2015) In addition, several previously reported affected cognitive domains were 
assessed.(Twigg et al., 2010) 
The intracranial volume (ICV) calculated by FreeSurfer did not differ significantly between groups (t-
test, P=·514) and student’s t-test was done on the ICV normalised data (i.e. volume/ICV) to assess 
between-group differences. Hierarchical cluster analysis was further undertaken to identify 
homogeneous groups of variables amongst differential (diff ∆) changes in brain volumes following the 
two interventions. 
During post-hoc analyses interregional connectivity and inter-domain relationships between the right 
thalami, somnolence (ESS test scores) and verbal episodic memory (delayed LM test scores) were 
explored with Pearson correlations; controlled for ICV and normalised for differential changes (diff∆%) 
from the baseline (diff∆=[V/domainpre-V/domainpost]/V/domain pre x100). All results were Bonferroni 
corrected for multiple comparisons.  
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4.4 RESULTS 
Fifty five OSA patients (81%) completed the study, in addition to 35 age- and education- matched 
healthy volunteers (Fig 4.1). Attrition was due to incomplete investigations in 10% (7/68) of the BSC 
group, and 9% (6/68) of the CPAP group. Mean (SD) age of OSA patients was 47·6(11·1) years, ODI 
36·6 (25·2) events/hour, and ESS 12·8 (4·9). Baseline demographic characteristics of participants are 
shown in Table 4.1. Baseline sleep characteristics are shown in Table 4.2. The baseline characteristics 
were similar between the CPAP with BSC group and BSC only group. Median CPAP use over one month 
was 5·0 (range 1·9-6·9) hours/night (Table 4.1). 
 
Table 4.1: Baseline characteristics of participants. 
 Controls BSCbaseline  CPAPbaseline  
Age (years) 43·5 (2·1) 46·8 (2·3) 49·9 (2·0) 
BMI (kg/m2) n/a 34·4 (5·1) 35·2 (2·9) 
Education (years) 15·0 (0·4) 14·6 (0·5) 14·7 (0·5) 
AHI (events/h) n/a 36·4 (4·0) 36·6 (5·0) 
ODI (events /h) 2·31 (0·2) 37·8 (4·5) 35·4 (5·2) 
ESS 6·18 (0·49) 12·44 (0·88) 13·14 (1·0) 
Median CPAP use (hours/night) n/a n/a 5 (1·9-6·9) 
Dexterity (right-handed) (%) 100 100 100 
Data presented as mean (SEM), median (25th-75th percentiles) or number of patients N (%). 
Abbreviations: Controls: healthy volunteers (N=35); BSC: baseline values for patients treated with best 
supportive care (BSC) (N=27); CPAP: baseline values for patients treated with continuous positive 
airway pressure (CPAP) with BSC (N=28); BMI: Body mass index, AHI: apopnea/hypopnea index. ODI: 
oxygen desaturation index; 
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Table 4.2: Sleep baseline characteristics of two groups of OSA patients 
 
Additional Baseline 
Characteristics 
 
N Mean SD Pa 
TST BSC 27 369·39 71·86 0·042 
CPAP 28 419·31 102·18   
Total Deep sleep BSC 27 52·32 31·69 0·684 
CPAP 28 56·17 37·64   
total REM BSC 27 64·10 37·91 0·611 
CPAP 28 69·38 38·58   
% deep sleep BSC 27 13·27 7·23 0·937 
CPAP 28 13·11 7·78   
% REM BSC 27 17·49 9·84 0·537 
CPAP 28 15·99 7·98   
Desats (events) BSC 27 235·19 140·77 0·786 
CPAP 28 248·11 203·96   
ODI (events/hour) BSC 27 37·83 23·24 0·726 
CPAP 28 35·42 27·41   
apnoeas/hypopnoeas 
(events) 
BSC 27 227·78 134·42 0·802 
CPAP 28 239·75 208·90   
AHI (events/hour) BSC 27 36·40 20·91 0·979 
CPAP 28 36·58 27·15   
AI (events/hour) BSC 27 15·00 16·61 0·418 
CPAP 28 19·73 25·31   
Time SaO2 <90% BSC 27 55·65 56·37 0·503 
CPAP 28 69·28 89·10   
aBonferroni corrected P values. Apart from the total sleep time, the baseline characteristics were 
broadly similar between the two groups. 
Abbreviations: TST: total sleep time; REM: rapid eye movement sleep; desats: deaturations; ODI: 
oxygen desaturation index; AHI: apnoea hyponea index; AI: arousal index; SD: standard deviation; C: 
BSC: best supportive care at baseline; CPAP: patients to be treated with continuous positive airway 
pressure (CPAP) at baseline. 
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4.4.1. Changes in brain morphology 
At baseline, hypotrophic changes were recorded in the left hippocampus, in the bilateral pallidus and 
the mid-posterior part of the corpus callosum of OSA patients (n=55) in comparison to those recorded 
in healthy controls (n=35) (Fig 4.2: pre-CPAP). Following one month of interventions, the between-
group comparison (patient groups vs healthy controls) no longer showed statistically significant 
hypotrophic changes in either of these structures, suggesting that adaptive neuroplastic changes have 
occurred (Table 4.3). The hierarchical cluster analysis further demonstrated the distinct alteration 
pattern for each intervention during this period (Fig 4.3), with the thalamic alterations in the CPAP 
group closely linked to wider core neurocircuitry adaptations, compared to the BSC group.  Of 
particular interest is the close clustering of the left and right hippocampi in the CPAP group, but not 
in the OSA group. The left and right cerebellum also form a cluster with the right and left thalamus, 
and right and left hippocampus in the CPAP group but not the BSC group. 
 
Table 4.3: The effect of one month of interventions on normalised volumes of structures that were 
registered hypotrophic at baseline. 
Structures Control  OSA  BSC CPAP  Pa PaBSC PaCPAP 
L Pallidum 0·1094 
(0·015) 
0·1026 
(0·015) 
0·1045 
(0·024) 
0·1067 
(0·017) 
0·039* 0·177 0·504 
L Hippocampus 0·2355 
(0·025) 
0·2244 
(0·03) 
0·2290 
(0·051) 
0·2381 
(0·027) 
0·071* 0·334 0·697 
R Pallidum 0·1028 
(0·015) 
0·0960 
(0·014) 
0·0974 
(0·020) 
0·0980 
(0·013) 
0·031* 0·177 0·172 
CC_Mid_Posterior 0·0296 
(0·006) 
0·0269 
(0·005) 
0·0279 
(0·006) 
0·0283 
(0·006) 
0·033* 0·270 0·400 
 
Data presented mean (SD), number of patients N. Mean values: percentage ratios of subcortical volumes 
to the ICV as determined by FreeSurfer.  P columns: P= OSA at baseline vs controls; P BSC= BSC vs controls; 
P CPAP= CPAP with BSC group vs controls. aBonferroni corrected P values. Abbreviations: R: right; L: left; 
CC: corpus callosum; ICV: intracranial volume; ODI: oxygen desaturation index; SD: standard deviation; C: 
Controls: healthy volunteers (N=35). OSA: baseline values for all obstructive sleep apnoea (OSA) patients 
before any intervention (N=55); BSC: patients treated with best supportive care (BSC) for one month 
(N=27); CPAP: patients treated with continuous positive airway pressure (CPAP) with BSC for one month 
(N=28). 
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Figure 4.2: 
Significant 
structural change in OSA patients Pre and Post CPAP treatment. The first row shows neuroanatomical structures that were noted as hypotrophic in OSA 
patients (N= 55) before any intervention, by comparison to matched healthy volunteers (N=35); bilateral globus pallidi, left hippocampi and mid posterior 
section of corpus callosum. The second row depicts hypertrophic changes noted in bilateral thalami following one month of treatment with CPAP; the 
longitudinal structural changes were calculated by normalization to the individual baseline volumes (refer to the equation). 
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Figure 4.3: 
Dendrograms depict relationships between structural changes in brain volumes following one month of intervention with the Continuous Positive Airway 
Pressure or Best Supportive Care treatment. Dendrograms were constructed using the results of Hierarchical Cluster Analysis (HCA) of the diff ∆ structural 
changes, using Average Linkage with squared Euclidean distance as a measure of distance (x-axis values). HCA resulted in the formation of clusters that were 
iteratively joined in a descending order of similarity. Resulting dendrograms show different patterns of neuroanatomical changes in patients with OSA 
following interventions with BSC alone (N=27) from those resulting post CPAP with BSC (N=28) treatment. The HCA findings also suggest that the thalamic 
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alterations (arrows) in the CPAP group are closely linked to a wider core of neurocircuitry adaptations and particularly that there is increased linkage between 
the left and right brain, including hippocampi (pink boxes). 
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The differential neuroanatomical structural changes at one month between the CPAP group and the 
BSC group were subsequently explored. In the CPAP group, a significant hypertrophic trend (Fig 4.2) 
for the right thalamus was recorded [mean diff∆% (SD): CPAP,4·04 (13·61) vs BSC,-2·29 (10·66); 
P=0·06]. No other statistically significant differences between groups were found (Table 4.4). 
 
Table 4.4: The effect of the Continuous Positive Airway Pressure or Best Supportive Care regimes at 
one month on changes in volumes of structures. 
 
Structure BSC N=27 SEM CPAP N=28 SEM Pa 
L CerebellumWhiteMatter 2·87% (2·44%) 4·27% 2·93% 0·716 
L CerebellumCortex -1·13% 1·65% 1·37% 2·62% 0·428 
L Thalamus -0·76% 2·30% 3·04% 2·55% 0·274 
L Caudate 5·08% 2·82% 1·26% 2·12% 0·281 
L Putamen 1·20% 2·65% 7·90% 3·23% 0·116 
L Pallidum 3·10% 3·10% 7·52% 5·49% 0·490 
BrainStem 0·49% 2·10% -0·11% 2·07% 0·840 
L Hippocampus 6·73% 3·97% 4·84% 2·91% 0·701 
L Amygdala -0·42% 3·70% 6·62% 3·79% 0·190 
R CerebellumWhiteMatter 3·36% 2·42% 3·48% 3·41% 0·977 
R CerebellumCortex -0·09% 2·13% 2·59% 2·71% 0·443 
RThalamus -2·29% 2·05% 4·04% 2·57% 0·061* 
R Caudate 2·92% 2·86% 0·98% 2·73% 0·626 
R Putamen 2·47% 2·83% 8·53% 3·35% 0·174 
R Pallidum 1·10% 3·02% 8·69% 6·92% 0·325 
R Hippocampus 2·60% 2·66% 3·51% 3·25% 0·831 
R Amygdala 0·33% 3·27% 8·83% 5·25% 0·179 
CC_Posterior 3·77% 3·44% -0·16% 3·18% 0·404 
CC_Mid_Posterior 7·38% 4·81% 5·07% 3·75% 0·705 
CC_Central 7·86% 3·90% 3·72% 2·80% 0·390 
CC_Mid_Anterior 7·50% 3·52% 3·27% 3·35% 0·388 
CC_Anterior 5·52% 3·04% 0·41% 3·45% 0·273 
Data presented mean (SEM), controlled for ICV and normalised for differential changes (diff%) from 
the baseline (diff=[V/domainpre-V/domainpost]/V/domain pre x100)· aBonferroni corrected P values· 
Significant difference between changes in two groups of patients after one month of CPAP (with BSC) 
or BSC alone · 
Abbreviations: R: right; L: left; CC: corpus callosum; ICV: intracranial volume; SEM: standard error of 
mean; C: BSC: best supportive care; CPAP: patients treated with continuous positive airway pressure 
(CPAP) for one month·  
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4.4.2. Changes in cognitive function 
At baseline, OSA patients showed significantly impaired cognitive processing in several domains in 
comparison to healthy controls (Table 4.5). Initially I used the analysis technique employed by Canessa 
(Canessa et al., 2011) and was able to reproduce after one month of interventions the 
improvementthat she recorded in the majority of tested domains after three months, compared to 
performance at baseline (Table 4.5). However, using more stringent analysis by compariing differential 
cognitive changes between interventions, only changes in sleepiness [ESS mean diff∆% (SD): CPAP, 
2.46 (39·97) vs BSC,-27·97 (46·46); P=0·012] and verbal episodic memory test scores [delayed LM 
mean diff∆% (SD): 23·41 (32·45) vs 57·20 (75·46); P=0·037] were statistically significant (Table 4.6).  
The NICE/HTA assessment of CPAP (McDaid 2009) found that CPAP therapy led to a mean reduction 
in ESS of 1.07 points in middle aged OSA patients. This was found to be clinically significant and CPAP 
therapy was found to be cost effective. In my study of young and middle aged patients the mean 
reduction in ESS after CPAP was 4.62 points.  
A recent analysis of the results of delayed LM testing in the American National Alzheimer’s 
Coordinating Centre database of over 20,000 subjects found that there was a mean difference of 5.2 
points between subjects diagnosed with mild cognitive impairment and those with normal cognition. 
The difference between patients diagnosed with mild cognitive impairment and those with 
Alzheimer’s dementia was 5.1 points (Chapman et al., 2016). In my study, the CPAP group showed an 
8.1 point increase after one month of CPAP.  
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Table 4.5: Changes in neurocognitive function using the analysis employed by Canessa (Canessa et al., 2011) 
Cognitive Tests Controls OSAbaseline BSC1month CPAP1month Pa Pa BSC PaCPAP 
immediate LM 47·06 (1·84) 36·36 (1·32) 41·70 ( 2·28) 44·43 ( 1·99) <0·001* 0·070 0·338 
delayed LM 29·79 (1·37) 22·25 (0·97) 27·33 (1·55) 29·93 (1·42) <0·001* 0·238 0·946 
ACE-R  94·91 (0·99) 90·55 (1·11) 90·70 (1·85) 91·86 (2·44) 0·008* 0·038 0·220 
Memory  24·18 (0·41) 22·05 (0·57) 23·07 (0·65) 23·79 (0·37) 0·009* 0·143 0·493 
Fluency  12·50 (0·3) 11·25 (0·3) 11·41 (0·49) 11·89 (0·45) 0·006* 0·050* 0·248 
Language  24·12 (0·71) 24·18 (0·37) 23·63 (0·68) 25·11 (0·24) 0·930 0·628 0·230 
SSF  9·00 (0·31) 8·33 (0·23) 7·93 (0·38) 8·18 (0·4) 0·079 0·032* 0·104 
SSB  8·65 (0·26) 7·65 (0·24) 7·37 (0·39) 8·18 (0·31) 0·009* 0·007* 0·250 
DSF  12·06 (0·33) 10·22 (0·31) 10·7 (0·4) 10·32 (0·51) <0·001* 0·011* 0·005* 
DSB  8·18 (0·39) 6·73 (0·31) 7·41 (0·47) 7·26 (0·52) 0·005* 0·21 0·157 
TMA  24·12 (1·18) 27·34 (1·04) 28·02 (1·56) 24·26 (1·28) 0·049* 0·047* 0·937 
TMB  41·23 (2·0) 62·02 (3·65) 61·53 (4·81) 51·05 (3·68) <0·001* <0·001* 0·017* 
ESS  6·18 (0·49) 12·80 (0·67) 12·11 (0·93) 8·18 (0·85) <0·001* <0·001* 0·038* 
 
Data presented as mean (SEM). Memory, fluency and language test scores were calculated from respective subtest scores of the Addenbrooke’s Cognitive 
Examination-Revised (ACE-R) test. Normality was checked using the Kolmogorov-Smirnov test. The plots were normally distributed so independent sample t-
test statistics were used to compare patient groups and controls. P columns: P= baseline OSA scores vs controls; P BSC= BSC vs controls; P CPAP= CPAP with 
BSC group vs controls. aBonferroni corrected P values. Abbreviations: Controls: baseline values for healthy volunteers (N=35). OSA: baseline values for all 
obstructive sleep apnoea (OSA) patients before any intervention (N=55); BSC: patients treated with best supportive care (BSC) for one month (N=27); CPAP: 
patients treated with continuous positive airway pressure (CPAP) with BSC for one month (N=28). ESS: Epworth sleepiness scale. TMB: Trail Making Test B; 
TMA: Trail Making Test A; DSF: Digit-span Forward Task; DSB: Digit-Span Backward Task; SSF: Spatial-span Forward Test; SSB: Spatial-span Backward Test; 
ACE-R: Addenbrookes Cognitive Examination- Revised ; LM: logical memory test. 
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Table 4.6: The effect of the Continuous Positive Airway Pressure or Best Supportive Care regimes at one 
month on changes in cognitive domains· 
 
 Cognitive test BSC N=27 CPAP N=28 Pa 
Mean SD Mean SD 
 
Immediate LM 14·28% 39·00% 34·78% 48·43% 0·090 
Delayed LM 23·41% 32·45% 57·20% 75·46% 0·037* 
ACE-R 2·63% 3·67% -0·34% 14·52% 0·306 
Memory (ACE) 11·93% 16·49% 5·63% 14·79% 0·141 
Fluency (ACE) 1·17% 10·81% 8·14% 25·49% 0·195 
Language (ACE) 0·45% 6·71% 1·45% 4·75% 0·523 
SSF -1·87% 21·75% 0·46% 30·66% 0·748 
SSB 1·03% 26·62% 8·46% 27·94% 0·317 
DSF 7·40% 23·88% 5·50% 33·34% 0·810 
DSB 12·43% 37·78% 16·22% 53·19% 0·762 
TMA -3·11% 18·97% -1·35% 24·89% 0·771 
TMB -6·99% 21·13% 3·17% 53·42% 0·361 
ESS 2·46% 39·97% -27·97% 46·46% 0·012* 
Data presented mean (SD), normalised for differential changes [diff∆(%)] from the baseline 
(diff=[score/domainpre-score/domainpost]/score/domainpre x100). aBonferroni corrected P values. 
Significant difference between changes in two groups of patients after one month of CPAP (with BSC) or 
BSC alone. Abbreviations:  ESS: Epworth sleepiness scale· TMB: Trail Making Test B ;TMA: Trail Making Test 
A; DSF: Digit-span Forward Task; DSB: Digit-Span Backward Task; SSF: Spatial-span Forward Test; SSB: 
Spatial-span Backward Test; ACE-R: Addenbrookes Cognitive Examination- Revised ; LM: logical memory 
test;·SD: standard deviation; C: BSC: best supportive care; CPAP: patients treated with continuous positive 
airway pressure (with BSC) for one month·  
 
In summary: the findings of a priori analyses between-interventions (CPAP vs BSC) demonstrated the 
differential neuroplastic cognitive and morphometric adaptations already after only one month of 
treatment (Figs 4.2 & 4.3; Tables: 4.4 & 4.6). 
 
4.4.3. Post hoc (Secondary) Analyses  
Secondary correlational analyses were dictated by the three significant findings of a priori investigations. I 
explored the pathomechanisms behind improvements in episodic memory, somnolence and the 
hypertrophic trend for the thalamus in the CPAP group (Figs 4.2 & 4.4). Significant correlation between 
improvement in sleepiness and volumetric changes in the brainstem (r= -0·37; P=0·05) was found (Fig 4.4), 
whilst improvements in verbal episodic memory were not obviously correlated to any singular 
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morphometric change. Similarly, hypertrophic changes in the right thalamus appeared strongly correlated 
to changes in bilateral cortical cerebellar (CC) and hippocampal (H) structures (left CC r= 0·77; P=1·96x10-6; 
right CC r= 0·75; P= 3·78x10-6; left H r= 0·49;P<0·01; right H r= 0·51; P<0·01), which was not the case for OSA 
patients who received only BSC intervention. In the CPAP group, thalamic changes were also found to be 
correlated with changes in overall cognitive functioning (ACE-R) scores (r=-0·554; P=0·002), attentional span 
changes (DSF, r=-0·499; P=0·007) and with changes in visuospatial working memory (SSB, r=-0·370; P=0·05). 
 
 
 
Figure 4.4 : Neuroplastic structural changes following one month of intervention with the Continuous 
Positive Airway Pressure or Best Supportive Care treatment. Potential strengthening in interregional 
connectivity between the non-dominant thalamus with hippocampus and (or) cerebellar cortex in OSA 
patients was noted only in the CPAP treated group (first row). In addition, in the same group of patients, 
improvement in sleepiness (as shown by the ESS), was strongly positively correlated to changes occurring 
in brainstem during this period (second row). 
 
Positive correlations between improvements in scores of verbal episodic memory and semantic subdomain 
of verbal fluency (fluency ACE-R) (r=0·406;P=0·032) that were otherwise negatively correlated in the BSC 
group (r=-0·190,P=0·343), were also shown. 
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Episodic memory showed significant positive correlation with span changes in the CPAP (r=0·451, P=0·02) 
vs BSC group (r=-0·081, P=0·69). ESS scores were not significantly correlated to changes in working memory 
in the CPAP (r=0·295, P=0·127), although were significant in the BSC group (r=0·591, P=0·001). The results 
of other neuroplastic adaptations and corresponding changes in cognitive domains are summarised in Table 
4.7. 
 
Table 4.7: Post Hoc targeted Interregional and Cognitive Domains Differential Correlations· 
CPAP N=28 r (P value) 
 R Thalamus ESS Delayed LM 
Brainstem ·741 (·000) -0·37 (·05) ·052(·791) 
L Cerebellum Cortex   0·77 (1·96 10-6) ·010(·961) -·023(·909) 
R Cerebellum Cortex  0·75 (3·78 10-6) ·027(·89) ·026(·897) 
L Hippocampus 0·49 (·01) -·224(·25) ·096(·628) 
R Hippocampus  0·51 (·01) -·233(·234) ·123(·53) 
ACE-R -·554(·002) ·062(·76) ·134(·496) 
DSB -·230(·24) 0·295 (·127) 0·451(·02) 
DSF -0·499(·007) ·224(·253) ·230(·239) 
SSB -0·370(·05) -·279(·150) ·289(·136) 
fluency ACE-R -0·554(·002) ·002(·992) 0·406 (·032) 
BSC N=27 r (P value) 
Interregional and Cognitive 
Domains Differential Correlations 
R Thalamus ESS Delayed LM 
Brainstem ·387 (·05) ·100(·618) ·105(·60) 
L Cerebellum Cortex  ·384 (·05) ·320(·104) -·059(·77) 
R Cerebellum Cortex  ·339 (·08) ·119(·55) -·192(·34) 
L Hippocampus ·366 (·06) ·188(·349) -·242(·22) 
R Hippocampus ·402 (·04) ·107(·59) -·120(·55) 
ACE-R -·022(·91) ·260(·19) ·370 (·06) 
DSF ·113(·57) ·499(·008) ·280(·16) 
DSB ·275(·16) 0·591(·001) -0·081(·69) 
SSB -·096(·63) ·245(·22) ·301(·13) 
fluency ACE-R ·181(·37) ·031(·88) -0·19 (·34) 
aBonferroni corrected P values. Significant difference between changes in two groups of patients after one 
month of CPAP (with BSC) or BSC use. Abbreviations:  ESS: Epworth sleepiness scale· TMB: Trail Making Test 
B ;TMA: Trail Making Test A; DSF: Digit-span Forward Task; DSB: Digit-Span Backward Task; SSF: Spatial-
span Forward Test; SSB: Spatial-span Backward Test; ACE-R: Addenbrookes Cognitive Examination- Revised 
; LM: logical memory test;·SD: standard deviation; C: BSC: best supportive care; CPAP: patients treated with 
continuous positive airway pressure (with BSC) for one month. 
 
4.5 DISCUSSION 
The main findings of this study were that just one month of CPAP treatment, combined with lifestyle 
modifications, can redress several cognitive and morphometric deficits in patients with moderate-severe 
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OSA. These data are consistent with the recovery of grey matter regions and cognition in patients with OSA 
reported by Canessa and colleagues (2011) to occur following three months of CPAP treatment (Canessa et 
al., 2011). Moreover, the same group has recently shown that appreciable recovery of cognition and white 
matter, including that in corpus callosum, occurs over the course of 12-month treatment with CPAP 
(Castronovo et al., 2014). My study is, to the best of my knowledge, the first time these findings have been 
replicated in much shorter timeframe (Gozal, 2013a). 
The baseline neuroanatomical and neurocognitive impairments recorded in OSA patients were comparable 
to previously reported neurocognitive deficits (Yaffe et al., 2007) and involved the neurocircuitry hubs 
formerly shown as specifically vulnerable to chronic sleep fragmentation and associated nocturnal cycles 
of intermittent hypoxia in clinical and preclinical studies (Gozal, 2013a; Rosenzweig et al., 2013a; 
Rosenzweig et al., 2013c; Yaffe et al., 2014; Rosenzweig et al., 2015). Specifically, hypotrophic changes in 
regions corresponding to hippocampal formation, basal ganglia and parts of the corpus callosum were 
suggested by neuroimaging investigations. Similarly, excessive daytime somnolence and significant 
impairments in cognitive domains of attention, working memory, verbal episodic memory and semantic 
memory were recorded in the OSA patients at baseline (Table 4.5). 
Of note is that a minimal improvement, both in cognitive and neuroanatomical measures, was 
demonstrated in the OSA patients randomized to BSC over one month (Table 4.4 & 4.5). Similar 
improvement in patients with OSA has been previously associated with the improved sleep quality and 
argues for the beneficial impact of diet, exercise and lifestyle modifications (Araghi et al., 2013). In addition 
to any intervention effects or natural neuro-homeostatic fluctuations, it is also possible that some of the 
cognitive changes may have represented practice effects.  
In order to distinguish the beneficial impact of CPAP from that of any other interventional modality, the 
between-groups comparison of normalized changes was performed. Consequently, three major constructs 
were highlighted. Specifically, neuroplastic hypertrophic changes in thalamus, decreased daytime 
somnolence and improvements in verbal episodic memory were shown as more likely to result from 
adaptive processes driven by treatment with CPAP, and as such merit further discussion. 
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4.5.1. Excessive Daytime Somnolence  
Somnolence is a major complaint in OSA, and whilst its exact neurological substrate is incompletely 
understood (Guilleminault & Brooks, 2001), it is likely that chronic low-level neuro-inflammation affects 
brain structures that participate in the initiation and maintenance of sleep and alertness (Rosenzweig et al., 
2015). In agreement with this notion, improvement in daytime somnolence following one month of 
treatment with CPAP was significantly correlated with neuroplastic alterations in brainstem (Fig 4.4) in my 
study. In addition, brainstem alterations were associated with hypertrophic thalamic changes, which were 
in turn closely correlated with alterations in bilateral cerebellar cortices and hippocampi (Fig 4.3). The 
neuroplastic stream of these associations correlated closely with changes in scores of tests of attentional 
regulation and working memory capacity (Fig 4.5). 
 
Figure 4.5: Schematic presentation of the neuroarchitecture behind working memory maintenance processes that 
might be implicated in improved daytime somnolence and verbal episodic memory by the CPAP treatment. Distributed 
nature of processes and representations involved to solve working-memory tasks is shown, with thalamus (central 
structure) acting as a functional interface between arousal and attentional regulation. The hippocampus (elongated 
green), structure most frequently reported affected by neuroimaging in OSA, is here proposed to bind aspects of 
working and episodic memory. The list of cognitive tests used in my study to investigate the impact of CPAP treatment 
on associated cognitive domains is also depicted. CPAP treatment leads to improvement in verbal episodic memory 
(green box), which may be due to the interplay of a cascade of subtle gradual changes in the semantic and verbal 
working memory. In addition, CPAP regime leads to the improvement of excessive daytime somnolence (yellow box), 
which in turn appears to be significantly correlated to ensuing brainstem alterations. The results of this study also 
suggest that comparable subjective tiredness has significantly less impact on the attention and maintenance of 
working memory capacity in patients treated with CPAP.  Abbreviations: CPAP: continuous positive airway pressure; 
BSC: best supportive care; LTM: long term memory; ESS: Epworth Sleepiness Scale.  
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It is possible that the findings of the study reported in this Chapter represent changes in consciousness and 
arousal regulation that can occur within one month, perhaps primarily driven by increased activity/plasticity 
of brainstem pathways. Many of these pathways are known to underlie rapidly generated brief shifts of 
arousal at times of increased cognitive and cortico-thalamic demand (Schiff, 2008). It follows that the 
findings of the present study might also suggest specific vulnerability of a thalamo-cortical oscillator to sleep 
fragmentation and nocturnal cycles of intermittent hypoxia, something that has been long suggested by 
neurophysiological and neuroimaging data in OSA (Rosenzweig et al., 2013a; Rosenzweig et al., 2013c). In 
cases of a faulty oscillator, distributed network activity and associated memory may suffer across long-
range cortico–cortical pathways, and within cortico–striatopallidal–thalamo-cortical loop volleys (Schiff, 
2008). 
It is notable that the findings also show that, whilst in untreated OSA patients changes in scores of tests of 
attention and working memory capacity were strongly affected by severity of their sleepiness, this 
significant association was all but negated by the effects of treatment with CPAP over one month (Fig 4.5). 
As patients with OSA have been shown to be more likely to experience a driving-related traffic accident, 
and given that such accidents have been shown as more likely in those who manifest greater daytime 
sleepiness, it can be argued that this finding implies strong clinical rationale for CPAP treatment even for a 
short duration (Gozal, 2013a; Malhotra et al., 2015; Rosenzweig et al., 2015). 
4.5.2. Thalamo-cortical Circuitry in OSA 
As already suggested, recruitment of central thalamic neurons via the brainstem occurs in response to 
increasing cognitive demand, stress and fatigue that reduce behavioral performance (Schiff, 2008). Through 
thalamic activation, neurons across the cerebral cortex and striatum can be depolarized, and their activity 
selectively gated by descending or ascending signals related to premotor attention and alerting stimuli 
(Schiff, 2008). 
In Chapter 1 I outlined how OSA could directly injure the thalamo-cortical neurons, or their prominent 
deafferentation as a result of multifocal, neuro-inflammatory brain processes, could lead to severe 
impairment of prefrontal functional integration and arousal regulation (Portas et al., 1998; McNab & 
Klingberg, 2008; Schiff, 2008; Rosenzweig et al., 2013c). In keeping with this suggestion, I now speculate 
that these findings show neuroplastic compensatory thalamic changes, instigated by one month of CPAP 
treatment, leading to a wider circuitry reorganization involving brainstem, cerebellum and hippocampal 
connectivity. This connectivity is seen both between these structures and between the left and right sides 
of the brain in the CPAP group but not the BSC group (Figs 4.2 & 4.4). I also propose that CPAP-driven 
adaptive processes further optimize activation of the thalamic system that acts as functional interface 
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between arousal and attentional regulation (Portas et al., 1998; Eriksson et al., 2015). This might then 
underlie positive subjective experience of decreased mental effort required in order to solve tasks following 
the CPAP treatment. 
4.5.3. Neurocognitive Architecture of Working and Episodic Memory in OSA 
One month of CPAP treatment resulted in a partial recovery of episodic- and working-memory capacity. A 
crucial role for working-memory in temporary information processing and guidance of complex behavior, 
as well as its impairment in OSA (Twigg et al., 2010), has been recognized (Eriksson et al., 2015). There is 
emerging consensus that working-memory maintenance results from the interactions among associative 
memory representations and basic processes, including attention, that are instantiated as reentrant loops 
between frontal and posterior cortical areas, as well as subcortical structures (McNab & Klingberg, 2008; 
Eriksson et al., 2015). In the present study, over one month, wider reorganization in a distributed memory 
system for associative learning occurred, e.g. thalamo-cortical changes were associated with changes in 
bilateral hippocampi and cerebellar cortices. None of these alterations were observed in the BSC group. 
It is of further interest that the hippocampus, the structure most frequently reported as affected by 
neuroimaging in OSA (Rosenzweig et al., 2013a; Rosenzweig et al., 2015) has recently been proposed to act 
as a major shared substrate for working and episodic memory (Eriksson et al., 2015). Axmacher and 
colleagues have suggested that the hippocampus plays a role in working-memory maintenance of multiple 
items by neural assemblies synchronized in the gamma frequency range, locked to consecutive phase 
ranges of oscillatory activity in the hippocampal theta range (Axmacher et al., 2010). Of note, a decrease in 
theta band has been shown to occur after apnoea and hypopnoea events in some patients with OSA, and 
CPAP has been shown to normalise EEG changes (Rosenzweig et al., 2014). 
4.5.4. Limitations 
Several limitations should be considered when interpreting the findings of this study; the cross-sectional 
design and strict exclusion criteria used disallow conclusions to be made regarding causality or interactions 
between OSA, its treatment, and various comorbidities such as hypertension and diabetes. Also, one cannot 
infer which, if any, interventional aspects of the lifestyle modifications might have contributed to observed 
changes. Furthermore, correlations between changes in regional volumes and neuropsychological scores 
were exploratory and hypothesis-generating. Their interpretation of presumed complex and diverse 
causalities remains a challenging issue for the future. Nonetheless, these findings indicate an important 
clinical message about the benefits of CPAP treatment. 
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4.5.5. Conclusions 
The results of this study show that one month of CPAP treatment provides a sufficient timeframe for 
rudimentary neuroplastic changes to occur within targeted brain structures of patients with moderate to 
severe OSA. These data lead to speculation that these structural changes provide a basic neurocognitive 
architectural scaffold for further reorganization, which underlies some of the observed functional recovery 
in working and episodic memory. 
This work is important and will impact on clinical practice. Currently there exists a cohort of people who 
have OSA but are not sleepy. NICE guidelines do not recommend offering these patients CPAP therapy as 
there is no evidence that it improves outcomes. However, these subjects are exposed to the same 
intermittent hypoxia and sleep fragmentation as sleepy OSA patients. If changes in brain structure and 
cognitive function are sequelae of  IH and/or sleep fragmentation, and these changes are at least partially 
reversible with CPAP therapy, then the guidelines will need to be updated. 
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Chapter 5 
CHANGES IN BRAIN MORPHOLOGY IN OLDER PEOPLE 
WITH OSA FOLLOWING CPAP TREATMENT 
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5.1 SUMMARY 
Published studies of brain structure in OSA have involved only young and middle-aged patients. However 
the population is aging and OSA is at least twice as common in older adults than the in the general 
population. Cognitive dysfunction and changes in brain structure are recognised phenomena in older 
people independent of sleep apnoea status. My previous studies had shown brain hypertrophy that I 
hypothesised was a result of dendritic sprouting and increased connectivity induced by ischaemic 
preconditioning. Animal models of neuroplasticity show that neurogenesis cannot take place beyond a 
certain age. Prior to the study presented in this chapter it was not known whether ischaemic 
preconditioning would lead to dendritic sprouting and brain hypertrophy in older patients with OSA. 
The objective of this study was to investigate whether the change in brain structure seen in young and 
middle aged patients after CPAP treatment would be seen in older OSA patients. 
MRI scans from 17 older people with OSA randomised to CPAP (mean [SD]: AHI, 34.1[20.2] events/h; 1 
woman; age 70.8 [4.1] years) and 17 randomised to BSC (mean [SD]: AHI, 19.3[15.4] events/h; 5 women; 
age 70.8 [3.3] years) were analysed to determine hippocampal subfield volume at baseline and at 6 months. 
A significant decrease in left fimbria volume was seen in the CPAP group (p=0.01). A significant increase in 
the left presubiculum volume was seen in the BSC group (p=0.028). No hippocampal hypertrophy was seen 
in the CPAP group. 
The findings presented in this study suggest that ischaemic preconditioning does not result in increased 
connectivity in older OSA patients in the same way as it does in young and middle-aged patients in Chapters 
3 and 4. This may be because dendritic sprouting has been switched off due to age, or because of prolonged 
exposure to IH. Alternatively it may be the result of poor CPAP compliance. 
Contributions: The study was designed by Glasser, McMillan, Rosenzweig and Kempton. The data were 
acquired by McMillan and Glasser. Analysis of the data wascarried out Glasser, Rosenzweig, Chih Cheng 
Tsai and Williams. Statistical analysis was carried out by Chih Cheng Tsai, Glasser and Rosenzweig. 
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5.2 INTRODUCTION 
As has been discussed in Chapters 1, 3 and 4, cognitive impairment is a well-recognised and important 
sequela of OSA. Chapters 3 and 4 focused exclusively on younger and middle aged people with OSA; 
however the role of aging in cognitive decline is well recognised. Therefore in the last experimental chapter 
presented in this thesis I have taken the opportunity to investigate the possible changes in brain 
morphology associated with OSA in older people aged > 65 years. 
5.2.1 The aging population 
The world’s population is ageing and by 2045 the number of older people (>60 years) will be more than the 
number of children (<15 years) (United Nations, 2007). In Europe this historical crossover occurred in 1995 
due to long term reductions in fertility and mortality, and by 2050 the ratio of older people to children will 
be 2:1 (Fig 5.1). This situation poses major social and economic challenges across Europe. For example in 
the UK, by 2040 the predicted requirement for long-term care will increase by 60%, at an additional cost of 
approximately £4 billion per annum (Karlsson et al., 2006). Therefore strategies to reduce age-related 
health care costs are vital. One approach could be to promote health care that maintains the independence 
of older people and OSA is a potential therapeutic target (Tarasiuk et al., 2008). 
 
 
Figure 5.1: The European population from the 2006 revision of the world population prospectors. The older 
population is expected to increase in the future, whereas the population under age 60 is expected to 
decrease. (United Nations, Department of Economic and Social Affairs, Population Division, Population 
Estimates and Projections Section. Fact Sheet, Series A, 7 March 2007)  
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5.2.2 The prevalence of obstructive sleep apnoea in older people 
The prevalence of OSA in younger people has been discussed in Chapter 1, section 1.2.2. In older people 
the prevalence of OSA is at least two fold greater, with estimates ranging between 13 and 32% (Hoch & 
Reynolds, 1990; Ancoli-Israel et al., 1995; Bixler et al., 1998; Young et al., 2002a; Hader et al., 2005a; Hass 
et al., 2005). The wide variation in these estimates is likely to reflect the different health status of the older 
populations studied and the definitions of the disease. A detailed review of the prevalence of OSA in older 
people is shown in Table 5.1. 
Table 5.1: Prevalence of obstructive sleep apnoea in older people 
Reference n 
Female 
(%) 
Age (yrs) Population 
Prevalence of OSA (%) 
AHI ≥5 
AHI ≥10 / 
≥15 
Carskadon et al 1981 40  55  62-86  Community  36     
Coleman et al 1981 83  28  66±5  Sleep Clinic  39     
McGinty et al 1982 26  0  64.4±4.4  Community     62  
Roehrs et al 1983 97  –  61-81  Sleep Clinic  27     
Smallwood et al 1983 30  20  50-80  Community  37     
Yesavage et al 1985 41  0  69.5±6.5  Both 73     
Hoch et al 1986 56  52  69.3±5.4  Community  5  4  
Knight et al 1987 27  NG  75.8±5.9  Primary Care  37     
Mosko et al 1988 46  65  68.7±6.7  Community  28  16  
Ancoli-Israel et al 1989 233  65  65-101  Nursing Home  70     
Hoch et al 1990 105  53  60-91  Community  26  13  
Philips et al1992 92  52  64.2±8.6  Community  15     
Ancoli-Israel et al 1995 
346  53  72.8±6.1  Community    30  
54  57  70.8±6.2  Community     32  
Bixler et al 1998 75  0  65-100  Community  31  24  
Young et al 2002 3448  –  60-99  Community  54  20  
Endeshaw et al 2004 58  76  77.7±6.7  Community  56  19  
Haas et al 2005 3643  52  70.2±6.9  Community  46  20  
Hader et al 2005 80  50  74.1±6.3  General Clinic  43  19  
OSA: obstructive sleep apnoea, AHI: apnoea-hypopnoea index. Table adapted from Glasser et al 2011. 
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5.2.3 Aetiology of sleep apnoea in older people 
The high prevalence of OSA in older people has led to debate regarding its causes and consequences in the 
elderly (Lévy et al., 1996; Lavie et al., 2005). Although the prevalence of CSA is increased in older people 
the majority of sleep disordered events are obstructive. The increase in OSA may be due to a generalised 
decrease in the size of the upper airway lumen in older people, specifically in males (Martin et al., 1997). 
Structural changes to the dimensions of the upper airway include a lengthening of the pharyngeal airway 
in both men (Shigeta et al., 2008) and women (Malhotra et al., 2006) and the descent of the hyoid bone 
(Kollias & Krogstad, 1999), particularly in individuals with long faces (Pae et al., 2008); leading to an increase 
in pharyngeal resistance. Even in healthy elderly people pharyngeal resistance is increased, compared to 
that in younger people; indicating a predisposition to airway collapse (Browne et al., 2001). 
The collapsibility of the pharyngeal airway is determined by the transmural pressure across the airway, 
which is in turn influenced by the extraluminal pressure (Chapter 1; Section 1.2.1). Fat tissue around the 
airway is a key factor in the development of OSA in middle aged people (Horner et al., 1989; Schwab et al., 
2003) and neck circumference has been shown to be a significant risk factor (Davies et al., 1992). Although, 
older people with OSA typically have a lower body mass index and neck circumference compared to younger 
patients with similar disease severity (Chung et al., 2009).  
Functionally, the response of the genioglossus muscle to negative pressure applied during wakefulness 
(Malhotra et al., 2006) and sleep (Eikermann et al., 2007) is reduced in older people, compared to younger 
people (Erskine et al., 1993). The response to hypoxia is also reduced (Klawe & Tafil-Klawe, 2003). Overall 
these changes result in reduced respiratory pump and upper airway muscle function at sleep onset 
(Worsnop et al., 2000a), and a more collapsible upper airway (Kirkness et al., 2008a) with the critical closing 
pressure being -8.3 (2.3) cmH2O in older people, compared to -16.0 (6.9) cmH2O younger people, 
independent of body mass index (Eikermann et al., 2007). This increased collapsibility of the pharyngeal 
airway in older people, may be the explanation for the reduced CPAP requirements in older people. The 
therapeutic level of CPAP being on average 2.5 cmH2O less than younger OSA patients with matched disease 
severity - mean (sd) CPAP level: Older patients 6.9 (1.9) cmH2O; Younger patients 9.4 (3.5) cmH2O) (Kostikas 
et al., 2006). 
5.2.4 Cognitive function in older people with OSA 
A decline in cognitive function is considered part of the aging process, and the ability to encode new 
memories is particularly impaired (Hedden & Gabrieli, 2004). OSA has also been shown to be associated 
with cognitive dysfunction (Redline et al., 1997; Adams et al., 2001; Ferini-Strambi et al., 2003; Naegele et 
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al., 2006; Quan et al., 2006; Twigg et al., 2010) –see Chapter 1, Section 1.3; however few of these studies 
have included older OSA patients. Mathieu et al found cognitive dysfunction was independently related to 
both OSA severity and increasing age, but the coexistence of both factors did not result in increased 
cognitive dysfunction (Mathieu et al., 2008). Ayalon et al showed cognitive dysfunction, on performance of 
the Go-No-Go cognitive task, in older OSA people, but no significant impairment when OSA and increasing 
age were considered separately (Ayalon et al., 2010). Finally, Cohen-Zion et al used the mini-mental state 
examination to study the effects of OSA on cognitive function in older patients and found a significant 
association between the severity of OSA and the self-reported severity of daytime somnolence. Again, 
however, once other variables (including total sleep time) were included in the model, only the relationship 
between cognitive impairment and excessive somnolence remained significant (Cohen-Zion et al., 2001; 
Cohen-Zion et al., 2004). 
When cognitive function is preserved in OSA patients, functional brain imaging has revealed that brain 
activation is increased, compared to the activation that occurs in healthy controls performing the same 
task. The association between preserved cognitive function, and greater activation in OSA patients suggests 
that increased cerebral recruitment is required to maintain cognitive performance (Ayalon et al., 2006). 
Similar preservation of cognitive function, with compensatory increased cerebral activation has been found 
in older people; however older patients with coexistent OSA show decreased cerebral activation and 
cognitive dysfunction (Ayalon et al., 2010). This suggests that age and OSA could have synergistic effects on 
cerebral activation and consequently cognitive function. 
5.2.5 Sleepiness in older people with OSA 
Sleep becomes more fragmented with age, independent of sleep apnoea (Mathur & Douglas, 1995; Boselli 
et al., 1998; Browne et al., 2003a), and there is a well documented age-related reduction in sleep quality 
(Bixler et al., 1984; Redline et al., 2004). These features of sleep in older people have led to the suggestion 
that older OSA patients may be habituated to the added disease-related sleep disruption of OSA, and 
therefore do not suffer symptoms of daytime sleepiness in the same way as younger patients. The large 
epidemiological study (Sleep Heart Health Study; n=5,407) of community dwelling adults (mean age 63, 
range 45-99 years) showed that age was associated with a reduction in subjective sleepiness, measured 
using the Epworth Sleepiness Scale (ESS) in females, but not in males (ESS, young (39-40) years vs older > 
80 yrs. Females 7.4 (4.4) vs 6.5 (4.0); Males 7.3 (4.3) vs 7.7 (4.7) (Unruh et al., 2008)]). Assuming age was 
associated with an increased prevalence of OSA, these data could be interpreted as support for the notion 
that older OSA patients are less sleepy than younger patients. Although in another study comparing older 
people with and without OSA (defined as an apnoea / hypopnoea index (AHI) >10 to 15 events per hour) 
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patients with OSA were more sleepy than those without OSA (Endeshaw, 2006). In older OSA patients, 
recruited from sleep clinics; subjective daytime sleepiness was found to be similar to that experienced by 
younger patients matched for disease severity and body mass index in one study (Browne et al., 2003b) and 
less in another (Chung et al., 2009). Thus the current information on the symptoms of sleepiness in older 
people with OSA is unclear. 
5.2.6 Changes in brain morphology in older people with OSA 
As discussed in Chapter 1, section x the majority of studies of brain structure in OSA patients show 
hippocampal changes (see Table 3.1), likely due to intermittent hypoxia. This is supported by animal models 
of intermittent hypoxia which have resulted in cognitive impairment and hippocampal hypotrophy (Chapter 
3, Section 3.2.1). However, there is increasing evidence that ischemic preconditioning may protect against 
some of the effects of hypoxaemia as discussed in Chapters 3 and 4. Again, this is supported by animal 
models. Rats with spatial memory deficits caused by intermittent hypoxia, demonstrated improvement 
cognitive performance associated with increased cell proliferation in the dentate gyrus (DG) of the 
hippocampus (Gozal et al., 2003a; Gozal et al., 2003b). Furthermore, it has been shown that mild 
intermittent hypoxia is neuroprotective. The results presented in Chapter 3 of the Brain MRI in middle-aged 
people with OSA, compared to healthy people appear to support this suggestion. Likewise the results in 
Chapter 4, where young and middle-aged patients with OSA have been compared to healthy people, before 
and after CPAP treatment also support the notion that OSA can cause both hyper and hypotrophy in 
different brain structures. The effects of OSA in older patients, who may have had undiagnosed OSA for a 
long period of time, and who have the normal changes in cognitive function associated with aging are not 
known. 
5.3 AIMS 
The aim of the study presented in this Chapter was to investigate the impact of CPAP treatment on 
hippocampal structure and cognitive function in older people with OSA, testing the hypothesis that treating 
intermittent hypoxia secondary to OSA with CPAP would be associated with changes in hippocampus 
morphology. To address this aim a pre-defined hippocampal sub-fields analysis was carried out on the brain 
MRI scans of older patients with OSA, before and after 6 months of CPAP treatment.  
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5.4 METHODS 
5.4.1. Trial design 
This study was a single-blinded (investigator blinded), parallel group, single centre, randomised controlled 
trial (RCT) of 6 months duration. Patients were randomised to receive either CPAP and Best Supportive Care 
or Best Supportive Care only. The trial design and recruitment is shown in Fig 5.2..   
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Figure 5.2 CONSORT diagram of patient recruitment, and progression through the study 
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5.4.2. Recruitment and Screening 
Patients were recruited from those referred to the Royal Brompton Hospital sleep clinics with possible OSA. 
Patients who had completed the control arm of a large multicentre randomised study to investigate the 
treatment of OSA in older people (The PREDICT study - (McMillan et al., 2014)), were also approached to 
take part in the study. Cognitive testing and sleep studies were performed in the Royal Brompton Hospital 
Clinical Research Facility. The brain MRI scans were completed in the Radiological Sciences Unit at Charing 
Cross Hospital, Imperial College Healthcare NHS trust. The study was approved by the National Research 
Ethics Committee (ref: 10/H0711/101) and patients gave written informed consent at the enrolment visit. 
The sponsor insurance and indemnity was provided by Imperial College London. 
Patients were eligible to participate if they were aged 65 years or older at the enrolment visit, with a 
diagnosis of OSA (defined as ≥ 4% SpO2; ODI > 7.5 events/hour). Patients were not eligible for the study if 
had any of the following: arterial awake oxygen saturation <90% on room air, FEV1 / FVC ratio <60%, 
substantial problems with sleepiness driving (in those who are still driving), currently using heavy good 
vehicle or professional service vehicle driving license, shift work, any very severe complication of OSA such 
that CPAP therapy was mandatory, inability to give informed consent or comply with the protocol, previous 
or current psychiatric disorders (including alcohol or drug abuse), psychotropic medications (including all 
sedating medications, anxiolytics, major tranquilizers, antipsychotics, hypnotics, anticonvulsants), 
neurological disorders, and a previous head injury resulting in loss of consciousness or notable cognitive 
deficit. 
Contraindication to undergoing the MRI scan, in particular metal within the body was also an exclusion 
criteria. The exclusion criteria for MRI were: pacemaker or pacing wires, aneurysm clips in the head, artificial 
heart valves or coronary stents, metal implants, cochlear implants, programmable shunts, deep brain 
stimulator or neurostimulator, and shrapnel or metal fragments in the body or eyes 
All patients potentially eligible to participate in the study were identified from sleep and respiratory clinics 
by myself or Dr McMillan. Once the diagnosis of OSA was confirmed they were contacted and offered an 
opportunity to take part in the study. Screening logs were kept documenting the number of patients 
assessed for eligibility and, if applicable, the reason(s) for non-inclusion. 
5.4.3. Data Collection 
Patients were randomized to receive either CPAP plus Best Supportive Care (see Chapter 4 for a full 
description) or Best Supportive Care alone. As discussed earlier in Chapter 4, Section 4.8.1 this was a 
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physical device trial, and hence the treatment allocation for the individual patients could not be concealed. 
Randomised occurred after patients had completed their enrolment visit, the morning after the sleep study. 
Patients were allocated on a one to one basis, using block randomisation stratified by disease severity 
(enrolment ESS > 9 v ≤ 9) and ODI (ODI >15 v <15). 
Both groups had identical schedules (see Table 5.2). Structured clinical assessments were performed at 
baseline and 6 months. All patients received a telephone call at 1 week to optimize CPAP adherence and 
offer additional support. Domiciliary overnight, pulse-oximetry was completed at 6 months. Table 5.3 
summarizes the assessment completed at each time point. Assessment visits were carried out in the Royal 
Brompton Hospital research laboratory and clinical research facility. Occasionally, research staff agreed to 
see a patient in their own home when the patient was unable to attend the hospital. 
The brain MRI scans were completed on a 3T scanner (Siemens, Germany) in the Radiological Sciences Unit 
at Charing Cross Hospital, Imperial College Healthcare NHS trust. The brain scan sequence was 
approximately 60 minutes and included T1 and T2 weighted and diffusion tension imaging. All MRI scans 
were done on the afternoon prior to the NPSG and randomization. The cognitive test panel was conducted 
in a quiet laboratory at 19.00 before their NPSG. Patients were asked to abstain from caffeinated beverages 
for the duration of their stay.  
Table 5.2 Visit schedule 
Time Event 
Day 1  
13.00 Patient arrival Royal Brompton Hospital: Consent and enrolment 
14.00 The Oxford Sleep Resistance Test 
15.00 Taxi to Charing Cross Hospital  
16.00 Brain MRI scan 
18.00 Patient returns to Royal Brompton Hospital 
Enrolment completed 
18.30 Evening meal  
19.00 Cognitive tests 
20.00 Set up for Nocturnal Polysomnogram 
Day 2  
08.00 Fasting bloods  
08.30 Breakfast  
09.00 Randomised and intervention delivered 
 
96 
 
Table 5.3 Summary of assessments by time point 
 
  
Assessments and Measurements Screening Baseline 
Week Month 
1 6 
Eligibility and exclusions *    
Informed consent and enrolment * *   
Nocturnal polysomnogram  *   
Overnight pulse oximetry    * 
Overnight respiratory polygraphy *    
Clinical assessment visit including sleep history  *  * 
Demographics   *   
Caffeine and alcohol intake   *  * 
Exercise history    *  * 
Anthropometry  *  * 
Blood pressure and resting pulse  *  * 
Fasting bloods   *  * 
Subjective sleepiness (Epworth Sleepiness Scale)  *  * 
Objective sleepiness (Oxford Sleep Resistance test)  *  * 
Disease specific quality of life (SAQLI)  *  * 
Mood (Hospital Anxiety and Depression Scale)  *  * 
Cognitive function  *  * 
Telephone call    *  
Continuous positive airway pressure adherence   * * 
Continuous positive airway pressure side effects   * * 
Adverse events   * * 
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5.4.3. Brain MRI analysis 
The change from baseline in brain morphology was measured in older OSA patients treated with CPAP and 
those treated with Best Supportive Care only. Images were processed using the FreeSurfer software 
package (version 5.3.0, available at http://surfer.nmr.mgh.harvard.edu/), which is fully automated (See 
Chapter 2, Section 2.5.2 for a full description). 
A hybrid watershed algorithm was used to segement the image, removing non-brain tissue and 
transforming the images into Talairach space. GM and WM were segmented. Once the hippocampus had 
been identified, it was segmented using Bayesian inference and a probabilistic atlas of hippocampal 
formation. This was based on manual segmentation of ultra-high resolution T1-weighted images of several 
participants (Van Leemput et al., 2009). Volumes from 7 subfields were generated; CA1, CA2-3, CA4-DG, 
subiculum, presubiculum (GM), fimbria (WM) and hippocampal fissure (CSF). 
5.4.4. Additional analysis 
The change in cognitive function from baseline to 6 months as measured in older OSA patients treated with 
CPAP and Best Supportive Care. The cognitive test panel is described in Chapter 2, Section 2.4. Changes in 
subjective sleepiness, measured by the ESS score (Chapter 2, Section 2.3.1) were also analysed. Treatment 
compliance was measured objectively by downloading a smart card in the CPAP machine at the 6 month 
visits. 
5.4.5. Sample Size 
The sample size calculations for this study were based on the cognitive data previously collected in our 
group (Twigg et al 2010). As well as the most recently published data at the time the protocol was devised 
(Canessa et al., 2011). These data (Table 5.4) indicated that between group differences could be calculated, 
at an alpha error level of 5% (corresponding to a 95% confidence interval) and a beta error level or Statistical 
Power [1 - Beta] of 80%, assuming CPAP treatment reverses any reduction in cognitive function in older 
patients with OSA to levels comparable to those seen in these healthy people. Therefore, 20 Patients in 
each group would demonstrate a difference in spatial span forwards and backwards test. 
The Stroop data had shown that the mean time to complete the test is 39 seconds in OSA patients, and 23 
seconds in healthy controls (SD 8.1). Assuming a more conservative difference of 8 seconds after CPAP, 
using an alpha error levels of 5% and a Beta error or 80%, it was calculated that 17 patients were required 
in each group to detect this difference. 
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Table 5.4 Cognitive tests with sample sizes 
Test 
Sample 
1 
 
Sample 
2 
 
Sample 
Size in 
both 
groups 
Mean Sd Mean Sd 
Spatial Span Forwards 8 2 6 1 10 
Spatial Span Backwards 8 2 5 1 5 
Logical Memory (immediate) 43 10 36 22 94 
Logical Memory (delayed) 27 7 22 7 31 
 
Previous MRI brain studies in OSA had shown a differences in brain structure between OSA patients and 
controls using sample size 7-21 (see Table 3.1) and changes in hippocampal structure had been found after 
3 months CPAP in a study of 17 patients (Canessa et al., 2011). Therefore a sample size of 44 (22 in each 
group) was assumed to be needed for the brain MRI analysis. This allowed for a 10% drop out (e.g. loss to 
follow-up, claustrophobia preventing MRI acquisition, inability to sleep in the laboratory). 
 
5.5 STATISTICAL METHODS 
Hippocampal sub-field volume produced by FreeSurfer were dividing by total intracranial volume to 
normalise the data. A student’s t-test was used to compare BSC and CPAP groups both at baseline and at 6 
months. Within group differences were analysed using paired t-tests. The 4 predefined groups (Best 
Supportive Care:baseline, BSC:6 months, CPAP:baseline, CPAP:6 months) were compared using ANOVA. 
Tukey’s Honest Significan Difference was employed for post-hoc analysis which compared CPAP:6 months 
with the other 3 groups independently. ANCOVA was used when an additional covariate (OSA severity) was 
added. All statistical analysis was performed using SPSS statistical software (version 21.0, SPSS Inc., Chicago, 
Illinois, USA). 
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5.6 RESULTS 
The screening and recruitment for this study were completed between January and December 2012. During 
this time there were 150 new patients with a potential diagnosis of OSA who were aged over 65. The 
CONSORT diagram shows recruitment (Fig 5.2). 144 individuals were screened, of whom 93 (65%) met the 
inclusion criteria. 57 eligible patients did not consent to entering the study and 36 (39%) patients were 
randomised. This was fewer than the 44 patients I had intended to study. One patient withdrew from the 
study for medical reasons and 1 patients was excluded from the analysis as he was found not to have OSA 
(AHI <5 events/h). 
The 6 month visits occurred between July 2012 and August 2013 with 34 patients completing the protocol. 
The main reasons for non inclusion were: not wishing to enter the study n=57 (53%), inability to have MRI 
n=18 (17%), unable to make contact after initial contact and providing a patient information sheets n=14 
(13%) and an inability to complete cognitive battery due to limited English n=8 (7%). 
5.6.1 Baseline data 
Seventeen patients were randomised to CPAP plus BEST SUPPORTIVE CARE; 19 to BEST SUPPORTIVE CARE 
alone. 28 (83%) were male with a mean age of 71 ranging from 65 to 77 years. 28 (82%) were white. Patients 
had a mean BMI of 30.8 (S.D. 4.9) Kgm2. No significant difference was found between the groups for age, 
years of education, BMI, neck circumference or BP. Baseline demographic and clinical data are shown in 
Table 5.5 and 5.6 respectively. 
By chance the CPAP group had more severe OSA: Arousal Index (events/TST) (p=0.01), 4% Apnoea 
/hypopnoea Index (p=0.02), Obstructive events/h (p=0.04) and 4% ODI (p=0.01) although subjective 
sleepiness, objective sleepiness and symptoms were similar between groups. The sleep data are shown in 
Table 5.7. 
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Table 5.5: Baselines demographics 
 
Best Supportive 
Care 
N=17  
Continuous positive 
airway pressure 
N=17 
Independent T test  
p value 
Age (years) 70.8 (3.3) 70.8 (4.1) 0.96 
Male sex N (%) 12 (71%) 16 (94%) Not tested 
Education (years) 15 (6) 14 (4) 0.36 
White N 15 14 Not tested 
Asian N 1 1 Not tested 
Other N 1 2 Not tested 
Body mass index (kg/m2) 31.4 (3.8) 30.1 (6.0) 0.46 
Neck circumference (cm) 42 (4) 43 (4) 0.63 
Caffeinated drinks /day 4 (3) 5 (3) Not tested 
Alcoholic drinks/week 4 (0-12) 3 (0-6) Not tested 
Smoking status 
N 
Never 6 10 Not tested 
Ex 11 5 Not tested 
Current 0 2 Not tested 
 
Data are mean (SD), median (25th-75th percentiles) or N number (%) as appropriate. As patients were 
randomised any differences that occurred between groups at baseline will be the result of chance. 
Statistical analysis by group was only completed after data collection was completed in parameters that 
may influence cognitive function. Parameters with small numbers were not tested. 
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Table 5.6 Baseline clinical characteristics 
 
Best Supportive 
Care 
N=17  
Continuous positive 
airway pressure 
N=17 
Independent  
T test  
p value 
Asthma/COPD N 4 1 Not tested 
Ischaemic Heart Disease N 7 7 Not tested 
Hypertension N 11 13 Not tested 
Diabetes N 4 5 Not tested 
Cerebral vascular Disease N 1 2 Not tested 
Systolic blood pressure (mmHg) 140.9 (22.4) 134.1 (17.5) 0.33 
Diastolic blood pressure (mmHg) 81.7 (11.6) 81.5 (15.1) 0.97 
 
COPD: Chronic Obstructive Pulmonary Disease. Data are mean (SD), median (25th-75th percentiles) or N 
number (%) as appropriate. As patients were randomised any differences that occurred between groups at 
baseline will be the result of chance. Statistical analysis by group was only completed after data collection 
was completed in parameters that may influence cognitive function. Parameters with small numbers were 
not tested. 
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Table 5.7 Baseline sleep measurements 
 
N Best Supportive 
Care 
N Continuous 
positive airway 
pressure 
Independent  
T test  
p value 
Epworth sleepiness score 17 9.4 (4.8) 17 9.4 (3.9) 1.0 
Oxford Sleep Resistance Test 
(minutes)  
16 26.6 (14.5) 16 26.6 (15.8) 0.99 
Sleep Apnoea Quality of Life Index 17 4.8 (1.5) 17 5.2 (0.9) 0.30 
Total sleep time (TST) (minutes) 14 291.5 (99.5) 15 352.7 (91.8) 0.097 
Sleep efficiency (%)  14 55.8 (16.6) 15 66.8 (13.1) 0.06 
Arousal index (events/TST)  15 17.1 (9.4) 15 30.9 (16.8) 0.01 
4% Apnoea /hypopnoea index 
(events/TST) 
17 19.3 (15.4) 17 34.1 (20.2) 0.02 
Apnoea index  17 6.6 (2.3 - 12.9) 17 23.9 (8.3 - 44 ) 0.06 
Obstructive events/h 17 4.7 (1.2-9.3) 17 
14.9 (4.8 – 
31.6) 
0.04 
Central events/h 17 0.5 (0.05 – 1.7) 17 1.1 (0.2 -6.4) 0.5 
4% Oxygen Desaturation index  17 18.3 (14.6) 17 35.1 (21.5) 0.01 
SpO2 Time < 90% (minutes) 17 62.6 (12.7-87.7) 17 
73.5 (6.4- 
148.7) 
0.72 
 
Data are mean (SD), median (25th-75th percentiles) or N number (%) as appropriate. As patients were 
randomised any differences that occurred between groups at baseline will be the result of chance. 
Statistical analysis by group was only completed after data collection was completed in parameters that 
may influence cognitive function. 
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5.6.2. Brain MRI: Hippocampal volume analysis 
Hippocampal volumes as absolute values and percentage of whole brain are shown in Table 5.8 along with 
hippocampal sub-fields volumes. There was a significant reduction in left fimbria volume after 6 months in 
the CPAP group (p=0.01), A significant increase in left presubiculum volume was seen after 6 months in the 
Best Supportive Care group (p=0.028) (Table 5.9). No other significant differences were seen between or 
among groups either before or after treatment, whether using OSA severity as a covariate or not (Table 
5.9). 
5.6.3. CPAP Adherence 
The overall CPAP adherence was measured at 6 months and results are shown in Table 5.10. Of the 17 
patients randomised to CPAP 7 patients had stopped using CPAP or had low CPAP adherence, although at 
the end of the trial 12 patients (including 2 with low use) requested they continue using CPAP. Only 5 
patients had over 4 hours a night of CPAP use. The median daily use was 3.4 (2.2) hours.  
The oxygen desaturation index was statistically different between groups at 6 months in favour of CPAP 3.0 
(10.7) vs. Best Supportive Care 20 (18.3) events/hour p<0.01. This is likely to be because pulse oximetry was 
only performed on one night at the end of the study, when the subjects knew their oxygen saturations were 
being measured, whereas compliance data was recorded by the device every night and downloaded at the 
end of the trial. Subjects were likely to be more compliant with CPAP on the night that they knew oximetry 
was being recorded than on other nights. 
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Table 5.8 Normalised mean hippocampal volume (mm3) and percentage of whole brain and 
hippocampal sub-fields volume (mm3) and percentage of hippocampus. 
 
 
BEST SUPPORTIVE CARE 
 
CPAP 
 
Pre-treatment Post-treatment 
 
Pre-treatment Post-treatment 
(Left) 
  
Whole hippocampus 3822.0 (0.254%) 3878.8 (0.259%) 
 
3785.8 (0.244%) 3817.5 (0.249%) 
Fimbria 55.8 (1.463%) 55.7 (1.432%) 
 
67.0 (1.779%) 61.4 (1.616%) 
CA1 338.3 (8.876%) 340.9 (8.811%) 
 
326.3 (8.700%) 339.1 (8.979%) 
CA2-3 950.2 (24.881%) 962.3 (24.861%) 
 
916.5 (24.304%) 926.0 (24.472%) 
CA4-DG 537.5 (14.057%) 550.0 (14.210%) 
 
508.7 (13.481%) 519.5 (13.699%) 
Subiculum 606.9 (15.922%) 611.0 (15.784%) 
 
583.1 (15.419%) 605.9 (15.924%) 
Presubiculum 419.6 (10.971%) 448.6 (11.576%) 
 
416.3 (10.978%) 415.8 (10.914%) 
Hippocampal fissure 40.5 (1.044%) 43.2 (1.104%) 
 
45.4 (1.166%) 46.3 (1.196%) 
(Right) 
  
Whole hippocampus 3973.3 (0.264%) 3904.5 (0.261%) 
 
3877.0 (0.249%) 3877.1 (0.253%) 
Fimbria 34.7 (0.875%) 37.2 (0.975%) 
 
42.4 (1.093%) 34.2 (0.888%) 
CA1 339.8 (8.551%) 345.1 (8.864%) 
 
338.9 (8.816%) 354.4 (9.194%) 
CA2-3 993.7 (25.029%) 996.0 (25.604%) 
 
964.78 (24.949%) 974.9 (25.165%) 
CA4-DG 563.2 (14.162%) 568.5 (14.589%) 
 
534.3 (13.826%) 543.1 (14.000%) 
Subiculum 624.4 (15.700%) 632.4 (16.285%) 
 
601.9 (15.561%) 610.5 (15.824%) 
Presubiculum 414.7 (10.449%) 427.7 (11.048%) 
 
410.1 (10.662%) 400.7 (10.431%) 
Hippocampal fissure 49.9 (1.256%) 49.2 (1.254%) 
 
41.8 (1.089%) 40.2 (1.061%) 
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Table 5.9 Student and paired t-tests. 
 
Student t-test 
 
Paired t-test 
 
Pre-CPAP vs. Pre-BEST 
SUPPORTIVE CARE 
Post-CPAP vs. Post-BEST 
SUPPORTIVE CARE 
 
Pre- vs. Post-BEST 
SUPPORTIVE CARE 
Pre- vs. Post-CPAP 
(Left) 
  
Whole hippocampus 0.437 0.429 
 
0.094 0.159 
Fimbria 0.207 0.432 
 
0.785 0.010* 
CA1 0.659 0.662 
 
0.674 0.310 
CA2-3 0.404 0.647 
 
0.956 0.813 
CA4-DG 0.148 0.271 
 
0.394 0.589 
Subiculum 0.332 0.780 
 
0.496 0.222 
Presubiculum 0.991 0.233 
 
0.028* 0.874 
Hippocampal fissure 0.362 0.593 
 
0.282 0.751 
(Right) 
  
Whole hippocampus 0.257 0.552 
 
0.427 0.489 
Fimbria 0.256 0.571 
 
0.323 0.162 
CA1 0.485 0.464 
 
0.219 0.120 
CA2-3 0.894 0.551 
 
0.145 0.580 
CA4-DG 0.332 0.140 
 
0.079 0.433 
Subiculum 0.771 0.487 
 
0.180 0.270 
Presubiculum 0.639 0.381 
 
0.054 0.508 
Hippocampal fissure 0.338 0.299 
 
0.975 0.759 
(* = P-value < 0.05)  
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Table 5.10 CPAP Adherence 
 
 
 Over 6 months 
Number randomised 17 
Number (%) analysed  17 (100%) 
Number of patient who used CPAP less than 
1 months or stopped  
7 (41%) 
Number of patients who requested to 
continue using CPAP 
12 (71%) 
Number using CPAP >4 hours/night N (%) 5 (29%) 
Median daily use (mean hours/night) 3.4 (2.2) 
 
 
5.7 DISCUSSION 
The main findings of this study were a decrease in left fimbrial volume after CPAP, and an increase in 
the left presubiculum volume. There was no demonstrate the increase in the hippocampal sub-field 
volumes in older patients with OSA, this was somewhat surprising as previous studies in younger and 
middle-aged patients with OSA have seen these differences (Chapters 3 and 4). Possible reasons 
including the poor adherence with CPAP treatment, loss of plasticity in brain tissue and limitations of 
the scans and their analysis are discussed in this Section of the Thesis. I will also try to explain these 
findings in the context of the improvements in attention and executive function. The cognitive data 
has previously presented by Dr McMillan in her PhD Thesis. 
5.7.1. Left fimbria volume decrease 
After 6 months of CPAP treatment, the only change in hippocampal sub-field volume seen was a 
decrease in the left fimbria. The fimbria is a collection of white matter that extends from the 
ventricular surface of the hippocampus into the fornix, which forms the largest efferent projection of 
subiculum into the hypothalamus (O'Mara et al., 2001). In animal models the fimbria is involved in 
working memory. If the fimbria are surgically damaged rats will perform poorly at tasks of working 
memory (Walker & Olton, 1984), (Sutherland & Rodriguez, 1989). It is of note that the patients in the 
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present study showed improvements in tasks of attention and executive function but not in tasks of 
working memory. 
5.7.2. Left presubiculum volume increase  
The presubiculum volume increased after 6 months of Best Supportive Care. The presubiculum lies 
between the hippocampus and the cortex and as such is an important site for both afferent and 
efferent pathways. It receives cortical input from the cingulate gyrus, and projects indirectly into the 
hippocampus via the entorhinal cortex (Cragg, 1965; Shipley, 1975; Vanhoesen & Pandya, 1975; 
Pandya et al., 1979 cited from Seltzer, 1979). It receives afferent projections from the hippocampus 
that ultimately lead to the cortex (Meibach & Siegel, 1975; Swanson & Cowan, 1975; Meibach & Siegel, 
1977; Rosene & Van Hoesen, 1977). It is known to be involved in spatial memory (Simonnet et al., 
2013).  
The volume increase does was not matched by an improvement in spatial memory or any other 
cognitive domain in patients in the BEST SUPPORTIVE CARE group but it could still represent real brain 
hypertrophy. Alternatively it could represent oedema as a result of changes in intracellular sodium 
and potassium concentrations induced by ischaemia (Kreisman & LaManna, 1999). Finally it could be 
a statistical quirk and not represent a real change.  
5.7.3. Absence of brain hypertrophy after CPAP 
There are several possible reasons for the absence of brain hypertrophy found this study in older 
people, compared to those in younger and middle-aged people presented in Chapters 3 and 4. These 
include: 
Poor adherence to CPAP treatment: CPAP only prevents apnoeas when it is actually being worn. Thus 
if the patient sleeps with CPAP for some of the night and without it for some of the night, he/she will 
still be exposed to intermittent hypoxia for the period CPAP is not worn. Although there is no formal 
definition of CPAP adherence, most studies use a cut-off of 4 hours/night. Using this definition 
between 29 and 83% of patients were not adhering with CPAP (Weaver & Grunstein, 2008). Factors 
that are associated with poor adherence include depression, increased nasal resistance, mild or severe 
OSA, mild symptomatology of OSA and poor education (Sawyer et al., 2011). Older men with nocturia 
as a result of prostate disease also use CPAP less, as they need to reapply the mask several times 
during the night (Wolkove et al., 2008). Additionally older people may be able to nap during the day, 
therefore poor nightime adherence may not present such a problem compared to younger people 
who have more demanding schedules. 
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After 3 months of CPAP, adherent patients (mean CPAP use 8.5 hours/night) showed significantly 
more improvement in multiple cognitive domains than non- adherent patients (mean CPAP use 3.9 
hours/night) (Aloia et al., 2003). A subsequent study showed that 21% of poor users (<2 hous/night), 
44% of moderate users (2-6 hours/night), and 68% of optimal users (>6 hours/night) exhibited 
memory performance in the clinically normal range following 3 months of CPAP (Zimmerman et al., 
2006). In the present study only 5 patients (29%) achieved good adherent and 7 (41%) used CPAP for 
less than a month in total over the 6 months. If CPAP leads to improved cognitive function because 
the removal of intermittent hypoxia leads to hippocampal hypertrophy, then this level of adherent 
may be ineffective. However although my patients did not show improved memory, they did 
demonstrate improvements in attention and executive function. 
Loss of neuroplasticity: Rodent studies suggest that neuroplasticity is maximal in the first 2 weeks of 
life and had significantly reduced after 6-12 months (Kuhn et al., 1996). Expression of highly 
polysialyted neural cell adhesion molecule, expressed by new neural cells, falls steadily from 2 months 
of age until it is virtually undetectable at 18 months (Seki & Arai, 1995). I do not think there is 
corresponding data for human brains, but it is plausible that the neuroplasticity seen in younger 
individuals may not be present in those aged 65 years and older. 
Daytime sleepiness: The older patients who took part in this study did not report being excessively 
sleepy (mean ESS 9.4). It is therefore possible that the relatively low burden of symptoms may mean 
that they had had undiagnosed OSA for many years. If this was the case they may also have had 
prolonged exposure to intermittent hypoxia and sleep fragmentation. There is some evidence that the 
effects of these insults are cumulative and that may mean that my older patients’ prolonged exposure 
has resulted in irreversible damage. In animal models, prolonged exposure to sleep deprivation 
suppresses hippocampal neuronal proliferation, differentiation, maturation and survival (Roman et 
al., 2005). 
The CA1 hippocampal sub-field has been shown to be especially sensitive to hypoxia (H.M. & P., 1998; 
Harrison & Eastwood, 2001). Irreversible CA1 injury can be the result of even short periods of induced 
ischaemia (Nitatori et al., 1995; Csernansky et al., 1998). Although other sub-fields may be more 
resilient, prolonged exposure to intermittent hypoxia may result in irreversible damage in these 
regions. This explanation would be particularly interesting with regards to the results presented in this 
Chapter. Memory impairment, which did show some resolution in younger patients in Chapter 4, did 
not improve in older patients in this study because memory is mediated by the hippocampus, and the 
hippocampal damage in older OSA patients was irreversible, either because of prolonged exposure to 
intermittent hypoxia and sleep fragmentation or because of age-related loss of neuroplasticity. The 
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improvements in attention and executive function seen in older patients in this study could have to 
be mediated by a different mechanism, perhaps sleepiness: Although ESS reduction in the CPAP group 
(baseline mean 9.4, post-CPAP mean 7.3) was not statistically significant; it may have been clinically 
significant. 
5.7.4. Limitations of the analysis 
I have discussed the limitations of FreeSurfer in Chapters 3 and 4. The same limitations mentioned 
previously would apply to this study also. Furthermore, in this study I limited our analysis to the 
hippocampus and its sub-fields. This was based on the observation that almost all studies of brain 
structure in OSA patients have shown hippocampal hypotrophy (Morrell & Glasser, 2011). 
Additionally, the first study to show an increase in grey matter volume after CPAP treatment showed 
this in the hippocampus. I was therefore surprised by the results found in the study presented here. 
However, in Chapter 4 is should be noted that thalamic hypertrophy and hippocampal hypotrophy 
was found. Therefore, it is possible that by only studying hippocampal sub-fields I have missed 
hypertrophy in the thalamus or other brain regions. Further analysis will help to clarify this point. 
5.7.5. Conclusion 
The results of this study have shown that after 6 months of BEST SUPPORTIVE CARE there was an 
increase in left presubiculum volume, and that after 6 months of CPAP there was a decrease in left 
fimbria volume. There was no evidence of CPAP induced hippocampal hypertrophy. 
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CHAPTER 6: GENERAL DISCUSSION 
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6.1.  SUMMARY OF FINDINGS  
OSA leads to changes in brain structure that are associated with cognitive dysfunction. However it 
was unclear if these changes were reversible and whether any resolution of brain hypotrophy would 
result in resolution of cognitive dysfunction. 
Study 1 (Chapter 3) was a cross-sectional study of brain structure in young and middle-aged patients 
with OSA. A new automated technique, FreeSurfer, was used to analyse MRI brain images of patients 
newly diagnosed with OSA compared to healthy controls. It is the first study to show that, as well as 
hypotrophy of brain tissue, OSA patients also have regions of hypertrophy within the hippocampus, 
an area of brain associated with memory. I propose that this hypertrophy was the result of ischaemic 
preconditioning, with IH leading to dendritic sprouting and increased connectivity and protection of 
brain function. 
Study 2 (Chapter 4) was a randomised controlled trial of CPAP’s effects on brain structure and 
cognitive function in young and middle-aged OSA patients. FreeSurfer was used to analyse MRI brain 
images of newly diagnosed OSA patients and healthy controls. In this study I also investigated a link 
between brain structure and brain function by analysing subjects’ performance in a battery of 
cognitive tests. In order to assess the effects of CPAP, OSA patients were then randomised to receive 
either CPAP or best supportive care for one month following which brain MRI and cognitive testing 
were repeated. I found hippocampal hypotrophy in OSA patients compared to healthy controls at 
baseline. However after one month of CPAP treatment this was no longer significant. Furthermore 
there was significant thalamic hypertrophy in the CPAP group compared to the BSC group. 
Hypertrophic changes in the right thalamus were strongly correlated to changes in bilateral cortical 
cerebellar and hippocampal structures. CPAP was also shown to significantly improve performance in 
tests of working memory. The association of improvement in working memory with wider 
reorganization in a distributed memory system for associative learning (thalamocortical changes 
associated with changes in bilateral hippocampi and cerebellar cortices) suggests that ischaemic 
preconditioning may be neuroprotective in young and middle-aged OSA patients. This leads to 
resolution of brain hypotrophy following treatment with CPAP. This resolution of brain structure in a 
system known to be involved in working memory may be the cause of the improvements in working 
memory following CPAP treatment that I found. 
Study 3 (Chapter 5) was a randomised controlled trial of CPAP’s effect on brain structure in older 
people with OSA. This is the first time the combined effects of OSA and aging on brain structure have 
been reported. MRI brain images were collected at baseline and 6 months after randomisation to 
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either CPAP or BSC. These were analysed using FreeSurfer, this time focusing specifically on 
hippocampal subfields, as I had already shown hippocampal hypertrophy in younger patients in study 
1 and the hippocampus is known to be a site of neurogeneration in ischaemic preconditioning in 
animal models.  I found fimbial hypotrophy after 6 months of CPAP in older patients with OSA but no 
hippocampal hypertrophy. This may be because aging leads to a reduction in neurogenerative 
capabilities inhibiting the protective effects of ischaemic preconditioning. Alternatively older OSA 
patients, who are less sleepy than younger patients, have actually had undiagnosed OSA for a long 
period, and prolonged exposure to IH has resulted in cessation of neurogeneration, as it has been 
shown to do in animal models. 
6.2. FUTURE RESEARCH 
Further work is needed to investigate the effects of intermittent hypoxia on brain structure and 
function in humans, as well as the protective role of ischaemic preconditioning. There is a subset of 
patients with moderate and severe OSA who are not symptomatically sleepy. Current guidelines state 
that these patients do not need to be offered CPAP. However these patients are still exposed to IH 
and sleep fragmentation. If either of these stimuli cause neural hypotrophy and cognitive dysfunction 
then these guidelines may have to be reviewed. This would be especially important if, as my thesis 
suggest, the hypotrophy and memory impairment are reversible in younger people, but not in older 
people, who may have been exposed to the stimuli for a prolonged period. 
We have shown an association between cognitive function and brain structure in OSA. It would be 
very difficult to prove a cause and effect mechanism, but more studies investigating both brain 
structure and cognitive function in large numbers of patients would provide strong circumstantial 
evidence. In order to achieve the required sample size, collaboration among multiple research teams 
would be required. This might lead to the development of a standard battery of cognitive tests, 
sensitive to the deficits seen in OSA patients, which would aid the comparison of results between 
groups and allow meta-analyses to be carried out. 
Driving ability is one of the most important complex cognitive tasks known to be impaired in OSA. This 
has a high cost, both economic and in terms of mortality. Current guidelines suggest that OSA patients 
can continue to drive if they are not excessively sleepy. IH may be linked to brain hypotrophy and 
impaired driving ability in non-sleepy OSA patients. I have shown that some patients do not develop 
brain hypertrophy after CPAP treatment but in fact develop further hypotrophy. Further research is 
required to investigate if brain hypotrophy in these patients is associated with impaired driving 
performance. If it is then the guidelines would need to be reviewed. 
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In order to further explore the relative roles of intermittent hypoxia and sleep fragmentation on brain 
structure, cognitive function and driving ability in OSA patients, I would propose a three armed 
randomised controlled trial. The first arm would be allocated to best supportive care and would 
therefore be exposed to both IH and sleep fragmentation. The second arm would be allocated to CPAP 
therapy and would therefore be exposed to neither IH nor sleep fragmentation. The third arm would 
be allocated to nocturnal oxygen therapy. This would not prevent airway obstruction and sleep 
fragmentation, but would remove the intermittent hypoxia. I would obtain MR brain images and 
measure cognitive function and driving simulator performance at baseline and again after 3 months 
of treatment. I would also study matched healthy controls at baseline and at three months.  
It would be intriguing to study brain structure and cognitive function in subjects with restless leg 
syndrome, whose sleep is fragmented but who are not exposed to intermittent hypoxia. However it 
would not be possible to determine whether any changes in brain structure in these subjects were the 
result of sleep fragmentation or whether they were caused by frequent leg movements, or were even 
the cause of the restless leg syndrome  The effects of pure sleep fragmentation could also be studied 
by using external interruptions to provoke frequent arousals from sleep in healthy controls over a 
prolonged period. However this approach would be difficult both practically and ethically. 
The effects of intermittent hypoxia during sleep could be studied by manipulating the atmospheric 
oxygen concentration while healthy controls slept. Again, to mimic OSA, this would need to be done 
over prolonged period and this would be difficult practically and ethically. However this approach 
could be used in animal models to determine at what point IH stops being beneficial. 
New automated techniques for the analysis of brain imaging are being developed constantly. Studies 
are needed to ensure that these techniques are validated in human brains, perhaps in post-mortem 
studies. Once they are proven to be valid they should be used to analyse as much data as possible. 
Automated analysis allows for rapid and relatively inexpensive analysis of large volumes of data. It is 
imperative that it used effectively and to its full potential. 
Poor CPAP compliance means that this treatment, which is highly efficacious at preventing apnoeic 
events if worn, cannot be considered the panacea of OSA treatment. Potential new techniques for 
preventing apnoeas may include nerve stimulation or less invasive devices to maintain airway patency. 
If the sequelae of OSA are mediated by IH then enriching inspired air with oxygen may be beneficial. 
Pharmacological cures must continue to be explored. Above all, preventative measures in the field of 
public health must succeed to prevent an epidemic of OSA and all the health problems it causes. 
6.3 CONCLUSION 
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The overall conclusion of the studied presented in this Thesis is that OSA leads to brain hypotrophy 
and cognitive impairment. However ischaemic preconditioning by IH may also be protective and lead 
to increased connectivity through dendritic sprouting. In younger patients ongoing dendritic sprouting 
leads to restoration of functional cognitive neural pathways after treatment. Future work should focus 
on preventing brain hypotrophy and ensuring effective treatment of OSA before neurogeneration 
switches off.  
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